Organic compounds

ABSTRACT

The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin&#39;s lymphoma.

FIELD OF USE

The present invention relates to human thymic stromal lymphopoietin(hTSLP) antibodies and especially those which neutralize hTSLP activity.It further relates to methods for using anti-hTSLP antibody molecules indiagnosis or treatment of hTSLP related disorders, such as asthma,atopic dermatitis, allergic rhinitis, fibrosis, inflammatory boweldisease and Hodgkin's lymphoma.

BACKGROUND OF THE INVENTION

Human thymic stromal lymphopoietin (hTSLP) (GenBank accession number:NM_(—)033035), an interleukin-7 (IL-7) like cytokine, which is producedby human epithelial stroma and mast cells, initiates the allergicresponse by the stimulation of dendritic cells (DC)¹. The deduced159-amino acid protein is 43% identical to mouse TSLP, contains a28-residue signal sequence, 6 cysteines, and 2 putative N-glycosylationsites. Native Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis(SDS-PAGE) analysis showed expression of a 23 kilo Dalton (kDa) protein,whereas the calculated molecular mass of the mature protein is 14.9 kDa,suggesting that hTSLP is glycosylated. hTSLP contains 7 basic C-terminalamino acids (aa)N-Lysine-Lysine-Arginine-Arginine-Lysine-Arginine-Lysine-C (KKRRKRK) and6 cysteins probably involved in disulfide bond formation.

hTSLP is highly expressed by epithelial cells of inflamed tonsils andkeratinocytes of atopic dermatitis and its expression is associated withLangerhans cell migration and activation.

The TSLP receptor complex is a heterodimer comprised of the TSLPreceptor (TSLPR) and IL-7 receptor alpha (IL-7Ra) chain. The receptor isexpressed primarily on monocytes and myeloid-derived DC, as well as on Blymphocytes³.

Allergy is the result of a complex immune cascade leading to thedysregulated production of the Thymus-derived helper cell type 2 (Th2)subset lymphocyte cytokines, the generation of allergen-specificIgE-producing B lymphocytes and the subsequent activation anddegranulation of mast cells upon allergen challenge.

DC play an important role in several models of allergy wherebyTSLP-activated human DC produce Th2-attracting chemokines but no IL-12,and induce naïve CD4- and CD8-antigen-positive T lymphocytedifferentiation into effector cells with a typical pro-allergicphenotype.

Atopic dermatitis (AD) represents a chronic, relapsing inflammatory skindisease with characteristic clinical features⁴. Genetic background,environmental exposures such as food allergens, aeroallergens, microbialantigens, or stress, and distinct immunological predispositions allcontribute to the development of periodic, itchy eczematous skin lesionsin afflicted patients. Several soluble factors have been shown to beincreased in the peripheral blood of patients with AD. These cytokinesand chemokines play an important role in regulating DC differentiation,activation and migration and are important in coordinating thetrafficking of immune cells. hTSLP, which is produced by humanepithelial stroma and mast cells, initiates the allergic response by thestimulation of DC. TSLP activated DC produce the CC chemokines thatinduce the chemotaxis and polarization of allergen-specific effectorlymphocytes⁵. Thus, epithelial- and stromal-cell-derived TSLP mightrepresent one of the factors initiating the allergic responses, andcould be a target for a curative therapeutic approach to allergy.

In recent studies, one anti-human TSLP polyclonal antibody was described(R&D Systems, AF1398). This antibody was produced in sheep immunizedwith purified E. coli-derived recombinant TSLP. Human TSLP specificsheep IgG was purified by hTSLP affinity chromatography. This polyclonalantibody was selected for its ability to neutralize hTSLP bioactivityand showed less than 1% cross-reactivity with recombinant murine TSLP.The Neutralization Dose₅₀ (ND₅₀) for this antibody was defined as thatconcentration of antibody required to yield one-half maximal inhibitionof the recombinant hTSLP activity on the responsive cell line mouseBaF/3 cells co-transfected with IL-7Ra and hTSLPR chains, as an assay.The ND₅₀ was determined to be approximately 0.05-0.25 μg/ml in thepresence of 0.5 ng/ml recombinant hTSLP. The disadvantage of polyclonalantibodies is that they are in a limited supply as there is a restrictedsupply of serum from the same treated animal. In addition, polyclonalantibodies recognize multiple epitopes on the same antigen and may haveundesired cross-reactivity. While polyclonal serum contains a mixture ofboth high and low affinity binders, targeting also a range of epitopes,a monoclonal antibody approach make sure to select the most usefulcandidate for a therapeutic use.

Animal-derived polyclonal antibodies when injected in humans constitutea foreign protein in a human host, they often elicit an antiglobulinresponse due to their immunogenicity in human. This antiglobulinresponse, which is predominantly directed against the constant domainsof the animal antibodies, usually precludes treatment after repeatedadministration.

SUMMARY OF THE INVENTION

An embodiment of the invention herein provides an isolated human orhumanized antibody or functional fragment thereof with anantigen-binding region that is specific for target protein hTSLP and theantibody or functional fragment thereof binds to hTSLP. In a relatedembodiment, the binding to hTSLP is determined at least by cell surfacehTSLP receptor binding preventing inflammatory mediator release.

In still another embodiment, the invention provides an isolatedantigen-binding region of an antibody or functional fragment thereof. Incertain embodiments, the isolated antigen-binding region includes anH-CDR1 region having an amino acid sequence selected from SEQ ID NOs:1-7, and conservative variants thereof. As described herein, theconservative variants include amino acid residues in any of the aminoacid sequences identified. In a related embodiment, the isolatedantigen-binding region is an H-CDR2 region having an amino acid sequenceselected from SEQ ID NOs: 8-25, and conservative variants thereof. Inanother related embodiment, the isolated antigen-binding region is anH-CDR3 region having an amino acid sequence selected from SEQ ID NO:26-31, and conservative variants thereof.

In another embodiment, the isolated antigen-binding region is an L-CDR1region having an amino acid sequence selected from SEQ ID NOs: 32-40,and conservative variants thereof. In still another related embodiment,the isolated antigen-binding region is an L-CDR2 region having an aminoacid sequence selected from SEQ ID NOs: 41-49, and conservative variantsthereof. In yet another related embodiment, the isolated antigen-bindingregion is an L-CDR3 region having an amino acid sequence selected fromSEQ ID NOs: 50-66, and conservative variants thereof.

In another embodiment, the isolated antigen-binding region is a heavychain having an amino acid sequence selected from one to three of SEQ ID1-31, and a sequence having at least 60, 70, 80, 90 or 95 percentsequence identity in the CDR regions with the CDR regions having SEQ IDNOs: 1-31. In a related embodiment, the isolated antigen-binding regionis a light chain having an amino acid sequence selected from one tothree of SEQ ID NOs: 32-66, and a sequence having at least 60, 70, 80,90 or 95 percent sequence identity in the CDR regions with the CDRregions having SEQ ID NOs: 32-66.

In a certain embodiment, the isolated antibody is an IgG. In anotherembodiment, the isolated antibody is an IgG1, IgG2 or an IgG4.

In yet another embodiment, the invention provides an isolated human orhumanized antibody or functional fragment thereof, having anantigen-binding region that is specific for an epitope of hTSLP, and theantibody or functional fragment binds to hTSLP surface receptors on acell. In a related embodiment, the invention provides an isolated humanor humanized antibody or functional fragment thereof, having anantigen-binding region that is specific for an epitope of target hTSLP,and the epitope contains one or more amino acid residues of amino acidresidues 1-112 of target hTSLP. In a related embodiment, the epitope isa conformational epitope.

In yet another embodiment, the antibody or functional fragment is a Fabor scFv antibody fragment. In a related embodiment, the isolatedantibody is an IgG. In another related embodiment, the isolated antibodyis an IgG1, IgG2 or an IgG4.

In another embodiment, the invention provides a pharmaceuticalcomposition having at least one of any of the above antibodies orfunctional fragments or conservative variants, and a pharmaceuticallyacceptable carrier or excipient therefor.

In still another embodiment, the invention provides for a transgenicanimal carrying a gene encoding any of the above antibodies orfunctional fragments thereof.

In certain embodiments, the invention provides a method for treating adisorder or condition associated with the presence of a cell having areceptor target hTSLP. The method involves administering to a subject inneed thereof an effective amount of any of the above pharmaceuticalcompositions. In a related embodiment, the disorder or condition to betreated is a respiratory disorder.

In another embodiment, the disorder or condition to be treated isbronchial asthma, which is a common persistent inflammatory disease ofthe lung characterised by airways hyper-responsiveness (AHR), mucusoverproduction, fibrosis and raised serum IgE levels. A significant rolefor TSLP has been demonstrated in a mouse model in which lung specificexpression of TSLP transgene induced allergic inflammation, goblet cellhyperplasia, subepithelial fibrosis and increased IgE levels (Zhou B, etal Nat. Immunol. 6: 1047-1053). Also mice lacking the TSLP-receptor wereprotected from allergic responses when exposed to aerosolized antigenchallenge. In addition a link between TSLP expression levels in lungepithelial cells and asthmatic disease severity has been described inhumans (Ying, S. B. et al. J. Immunol. 174: 8183-8190).

In another embodiment, the disorder or condition to be treated is atopic(allergic) dermatitis, which is the most common skin disease inchildhood and is characterized by intense pruritus and chroniceczematous plaques. A significant role for TSLP has been demonstrated ina mouse model in which skin specific expression of TSLP transgeneinduced eczematous skin lesions containing inflammatory cellinfiltrates, an increase in circulating Th2 cells and an increase inserum IgE (Yoo, J. et al. J. Exp. Med. 202: 541-549). Also in humansTSLP has been found to be highly expressed in tissue sections of atopicdermatitis lesions which was associated with Langerhans cell migrationand activation (Soumelis, V. et al. Nat. Immunol. 3: 673-680).

In another embodiment, the disorder or condition to be treated isselected from other inflammatory or obstructive airways diseases andconditions such as COPD, acute lung injury (ALI), acute/adultrespiratory distress syndrome (ARDS), dyspnea, allergic airwayinflammation, small airway disease, lung carcinoma, acute chest syndromein patients with sickle cell disease and pulmonary hypertension, as wellas exacerbation of airways hyperreactivity consequent to other drugtherapy, in particular other inhaled drug therapy.

In another embodiment, the disorder or condition to be treated isbronchitis of whatever type or genesis including, e.g., acute,arachidic, catarrhal, croupus, chronic or phthinoid bronchitis.

In another embodiment, the disorder or condition to be treated includespneumoconiosis (an inflammatory, commonly occupational, disease of thelungs, frequently accompanied by airways obstruction, whether chronic oracute, and occasioned by repeated inhalation of dusts) of whatever typeor genesis, including, for example, aluminosis, anthracosis, asbestosis,chalicosis, ptilosis, siderosis, silicosis, tabacosis and byssinosis.

In another embodiment, the disorder or condition to be treated isselected from atopic rhinitis (hay fever) and chronic sinusitis.

In another embodiment, the disorder or condition to be treated isselected from other inflammatory conditions of the skin, for example,psoriasis or lupus erythematosus.

In another embodiment, the disorder or condition to be treated isinflammatory bowel disease, such as ulcerative colitis and Crohn'sdisease.

In another embodiment, the disorder or condition to be treated isselected from other fibrotic conditions, such as systemic scelrosis,liver fibrosis, pulmonary fibrosis, idiopathic pulmonary fibrosis orfibroid lung.

In another embodiment, the disorder or condition to be treated is tumourrecurrence or metastasis Inhibition of Th2 cytokines has been shown toenhance anti-viral vaccines in animal models and may be beneficial inthe treatment of HIV and other infectious diseases [Ahlers, J. D., etal. Proc Natl Acad Sci USA, 2002].

In another embodiment, the disorder or condition to be treated is arespiratory viral infection, which exacerbates underlying chronicconditions such as asthma, chronic bronchitis, COPD, otitis media, andsinusitis. The respiratory viral infection treated may be associatedwith secondary bacterial infection, such as otitis media, sinusitis orpneumonia.

In another embodiment, the disorder or condition to be treated isselected from other diseases or conditions, in particular diseases orconditions having an inflammatory component, for example, diseases ofthe bone and joints including rheumatoid arthritis, psoriatic arthritis,and other diseases such as atherosclerosis, multiple sclerosis, andacute and chronic allograft rejection, e.g. following transplantation ofheart, kidney, liver, lung or bone marrow.

In another embodiment, the disorder or condition to be treated isendotoxic shock, glomerulonephritis, cerebral and cardiac ischemia,Alzheimer's disease, cystic fibrosis, virus infections and theexacerbations associated with them, acquired immune deficiency syndrome(AIDS), multiple sclerosis (MS), Helicobacter pylori associatedgastritis, and cancers, particularly the growth of ovarian cancer.

In another embodiment, the disorder or condition to be treated is thesymptoms caused by viral infection in a human which is caused by thehuman rhinovirus, other enterovirus, coronavirus, herpes viruses,influenza virus, parainfluenza virus, respiratory syncytial virus or anadenovirus.

Treatment in accordance with the present invention may be symptomatic orprophylactic.

The effectiveness of an agent of the invention in inhibitinginflammatory conditions, for example in inflammatory airways diseases,may be demonstrated in an animal model, e.g. mouse, rat or rabbit model,of airway inflammation or other inflammatory conditions, for example asdescribed by Wada et al, J. Exp. Med (1994) 180:1135-40; Sekido et al,Nature (1993) 365:654-57; Modelska et al., Am. J. Respir. Crit. Care.Med (1999) 160:1450-56; and Laffon et al (1999) Am. J. Respir. Grit.Care Med. 160:1443-49.

In yet another embodiment, the invention provides a method foridentifying a cell having a receptor for hTSLP. This method involvescontacting the cell with any of the above antibodies or antibodyfragments further having a detectable label. The label is radioactive,fluorescent, magnetic, paramagnetic, or chemiluminescent. The methodfurther can involve any of the above imaging or separating the labeledcell.

In another embodiment, any of the above human or humanized antibodies orantibody fragments are synthetic.

In another embodiment, the invention provides a pharmaceuticalcomposition and an additional therapeutic agent.

The additional therapeutic agent can be selected from the groupconsisting of

anti-inflammatory, bronchodilatory, antihistamine or anti-tussive drugsubstances, particularly in the treatment of obstructive or inflammatoryairways diseases such as those mentioned hereinbefore, for example aspotentiators of therapeutic activity of such drugs or as a means ofreducing required dosaging or potential side effects of such drugs. Atherapeutic agent of the invention may be mixed with the other drugsubstance in a fixed pharmaceutical composition or it may beadministered separately, before, simultaneously with or after the otherdrug substance. Accordingly the invention includes a combination of anagent of the invention as hereinbefore described with ananti-inflammatory, bronchodilatory, antihistamine or anti-tussive drugsubstance, said agent of the invention and said drug substance being inthe same or different pharmaceutical composition.

Suitable anti-inflammatory drugs include steroids, in particularglucocorticosteroids such as budesonide, beclamethasone dipropionate,fluticasone propionate, ciclesonide or mometasone furoate, or steroidsdescribed in WO 02/88167, WO 02/12266, WO 02/100879, WO 02/00679(especially those of Examples 3, 11, 14, 17, 19, 26, 34, 37, 39, 51, 60,67, 72, 73, 90, 99 and 101), WO 03/35668, WO 03/48181, WO 03/62259, WO03/64445, WO 03/72592, WO 04/39827 and WO 04/66920; non-steroidalglucocorticoid receptor agonists, such as those described in DE10261874, WO 00/00531, WO 02/10143, WO 03/82280, WO 03/82787, WO03/86294, WO 03/104195, WO 03/101932, WO 04/05229, WO 04/18429, WO04/19935 and WO 04/26248; LTB4 antagonists such as BIIL 284, CP-195543,DPC11870, LTB4 ethanolamide, LY 293111, LY 255283, CGS025019C,CP-195543, ONO-4057, SB 209247, SC-53228 and those described in U.S.Pat. No. 5,451,700; LTD4 antagonists such include montelukast,pranlukast, zafirlukast, accolate, SR2640, Wy-48,252, ICI-198615,MK-571, LY-171883, Ro 24-5913 and L-648051; PDE4 inhibitors suchcilomilast (Ariflo® GlaxoSmithKline), Roflumilast (Byk Gulden), V-11294A(Napp), BAY19-8004 (Bayer), SCH-351591 (Schering-Plough), Arofylline(Almirall Prodesfarma), PD189659/PD168787 (Parke-Davis), AWD-12-281(Asta Medica), CDC-801 (Celgene), SelCID™ CC-10004 (Celgene),VM554/UM565 (Vernalis), T-440 (Tanabe), KW-4490 (Kyowa Hakko Kogyo), andthose disclosed in WO 92/19594, WO 93/19749, WO 93/19750, WO 93/19751,WO 98/18796, WO 99/16766, WO 01/13953, WO 03/104204, WO 03/104205, WO03/39544, WO 04/000814, WO 04/000839, WO 04/005258, WO 04/018450, WO04/018451, WO 04/018457, WO 04/018465, WO 04/018431, WO 04/018449, WO04/018450, WO 04/018451, WO 04/018457, WO 04/018465, WO 04/019944, WO04/019945, WO 04/045607 and WO 04/037805; A_(2A) agonists such as thosedescribed in EP 1052264, EP 1241176, EP 409595A2, WO 94/17090, WO96/02543, WO 96/02553, WO 98/28319, WO 99/24449, WO 99/24450, WO99/24451, WO 99/38877, WO 99/41267, WO 99/67263, WO 99/67264, WO99/67265, WO 99/67266, WO 00/23457, WO 00/77018, WO 00/78774, WO01/23399, WO 01/27130, WO 01/27131, WO 01/60835, WO 01/94368, WO02/00676, WO 02/22630, WO 02/96462, and WO 03/086408; and A_(2B)antagonists such as those described in WO 02/42298.

Suitable bronchodilatory drugs include anticholinergic or antimuscarinicagents, in particular ipratropium bromide, oxitropium bromide,tiotropium salts and CHF 4226 (Chiesi), and glycopyrrolate, but alsothose described in EP 424021, U.S. Pat. No. 3,714,357, U.S. Pat. No.5,171,744, WO 01/04118, WO 02/00652, WO 02/51841, WO 02/53564, WO03/00840, WO 03/33495, WO 03/53966, WO 03/87094, WO 04/018422 and WO04/05285; and beta-2 adrenoceptor agonists such as albuterol(salbutamol), metaproterenol, terbutaline, salmeterol fenoterol,procaterol, and especially, formoterol, carmoterol and pharmaceuticallyacceptable salts thereof, and compounds (in free or salt or solvateform) of formula I of WO 00/75114, which document is incorporated hereinby reference, preferably compounds of the Examples thereof, e.g.(5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one)and pharmaceutically acceptable salts thereof, as well as compounds (infree or salt or solvate form) of formula I of WO 04/16601, and alsocompounds of EP 1440966, JP 05025045, WO 93/18007, WO 99/64035, US2002/0055651, WO 01/42193, WO 01/83462, WO 02/66422, WO 02/70490, WO02/76933, WO 03/24439, WO 03/42160, WO 03/42164, WO 03/72539, WO03/91204, WO 03/99764, WO 04/16578, WO 04/22547, WO 04/32921, WO04/33412, WO 04/37768, WO 04/37773, WO 04/37807, WO 04/39762, WO04/39766, WO 04/45618 WO 04/46083, WO 04/80964, EP1460064, WO 04/087142,WO 04/089892, EP 01477167, US 2004/0242622, US 2004/0229904, WO04/108675, WO 04/108676, WO 05/033121, WO 05/040103 and WO 05/044787.

Suitable dual anti-inflammatory and bronchodilatory drugs include dualbeta-2 adrenoceptor agonist/muscarinic antagonists such as thosedisclosed in US 2004/0167167, WO 04/74246 and WO 04/74812.

Suitable antihistamine drug substances include cetirizine hydrochloride,acetaminophen, clemastine fumarate, promethazine, loratidine,desloratidine, diphenhydramine and fexofenadine hydrochloride,activastine, astemizole, azelastine, ebastine, epinastine, mizolastineand tefenadine as well as those disclosed in JP 2004107299, WO 03/099807and WO 04/026841.

Combinations of therapeutic agents of the invention and anticholinergicor antimuscarinic agents, steroids, beta-2 agonists, PDE4 inhibitors,dopamine receptor agonists, LTD4 antagonists or LTB4 antagonists mayalso be used. Other useful combinations of agents of the invention withanti-inflammatory drugs are those with other antagonists of chemokinereceptors, e.g. CCR-1, CCR-3, CCR-4, CCR-5, CCR-6, CCR-7, CCR-8, CCR-9and CCR10, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, particularly CCR-5antagonists such as Schering-Plough antagonists SC-351125, SCH-55700 andSCH-D, Takeda antagonists such asN-[[4-[[[6,7-dihydro-2-(4-methylphenyl)-5H-benzocyclohepten-8-yl]carbonyl]amino]phenyl]-methyl]-tetrahydro-N,N-dimethyl-2H-pyran-4-aminiumchloride (TAK-770), CCR-5 antagonists described in U.S. Pat. No.6,166,037 (particularly claims 18 and 19), WO 0066558 (particularlyclaim 8), WO 0066559 (particularly claim 9), WO 04/018425 and WO04/026873.

The additional therapeutic agent may also be selected from the groupconsisting of other cytokine binding molecules, particularly antibodiesof other cytokines, in particular a combination with an anti-IL4antibody, such as described in PCT/EP2005/00836, an anti-IgE antibody,such as Xolair®, an anti-IL31 antibody, an anti-IL31R antibody, ananti-IL13 antibody, such as described in WO05/007699, an anti-endoglinantibody, an anti-IL1b antibody, an anti-TSLPR antibody or anotheranti-hTSLP antibody.

In a certain embodiment, the invention provides an antibody having afirst amino acid sequence which is a heavy chain selected from one tothree of SEQ ID NOs: 1-31, and a sequence having at least 60, 70, 80, 90or 95 percent sequence identity in the CDR regions with the CDR regionshaving SEQ ID NOs: 1-31; and a second amino acid sequence which is alight chain selected from one to three of SEQ ID NOs: 32-66, and asequence having at least 60, 70, 80, 90 or 95 percent sequence identityin the CDR regions with the CDR regions shown in SEQ ID NOs: 32-66.

In still another embodiment, the invention provides an immunoconjugatemade out of a first component which is an antibody or fragment thereofand a second component having a second amino acid sequence. For example,the immunoconjugate is a cytotoxin, or the immunoconjugate is a bindingprotein or antibody having a binding specificity for a target that isdifferent from hTSLP.

In certain embodiments, the invention provides for a bispecificantibody.

In another embodiment, the invention provides a kit having an antibodyor antibody fragment thereof. In some embodiments, the kit furthercontains a pharmaceutically acceptable carrier or excipient therefore.In other related embodiments, the antibody in the kit is present in aunit dose. In yet another related embodiment, the kit includesinstructions for use in administering to a subject.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 describes the HuCAL® Fab expression vector pMORPH®X9_Fab_FH(carrying anti-TSLP Fab MOR04494)F

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to isolated antibodies, particularly humanantibodies, that bind specifically to hTSLP and that inhibit functionalproperties of hTSLP. In certain embodiments, the antibodies of theinvention are derived from particular heavy and light chain sequencesand/or comprise particular structural features such as CDR regionscomprising particular amino acid sequences. The invention providesisolated antibodies, methods of making such antibodies, immunoconjugatesand bispecific molecules comprising such antibodies and pharmaceuticalcompositions containing the antibodies, immunconjugates or bispecificmolecules of the invention. The invention also relates to methods ofusing the antibodies to inhibit a disorder or condition associated withthe presence of cell receptor target hTSLP, for example, in thetreatment of an inflammatory or allergic condition, particularly aninflammatory or obstructive airways disease.

In order that the present invention may be more readily understood,certain terms are first defined. Additional definitions are set forththroughout the detailed description.

The term ‘hTSLP’ is a reference to human TSLP. The present inventionprovides antibodies to human TSLP, especially human antibodies, that arecross-reactive with non-human primate TSLP, including cynomolgus andrhesus monkey TSLP. Antibodies in accordance with some embodiments ofthe present invention may recognise a variant truncated isoform of TSLPin which the protein terminates at the alanine at residue 99 resultingin the last 60 amino acids of the C-terminus being deleted and also ansingle nucleotide polymorphism (SNP) of TSLP in which the cysteineresidue at amino acid position 90 is replaced by tyrosine. The term“immune response” refers to the action of, for example, lymphocytes,antigen presenting cells, phagocytic cells, granulocytes, and solublemacromolecules produced by the above cells or the liver (includingantibodies, cytokines, and complement) that results in selective damageto, destruction of, or elimination from the human body of invadingpathogens, cells or tissues infected with pathogens, cancerous cells,or, in cases of autoimmunity or pathological inflammation, normal humancells or tissues.

A “signal transduction pathway” refers to the biochemical relationshipbetween a variety of signal transduction molecules that play a role inthe transmission of a signal from one portion of a cell to anotherportion of a cell. As used herein, the phrase “cell surface receptor”includes, for example, molecules and complexes of molecules capable ofreceiving a signal and capable of the transmission of such a signalacross the plasma membrane of a cell. An example of a “cell surfacereceptor” of the present invention is the hTSLP receptor to which thehTSLP protein molecule binds.

The term “antibody” as referred to herein includes whole antibodies andany antigen binding fragment (i.e., “antigen-binding portion”) or singlechains thereof. A naturally occurring “antibody” is a glycoproteincomprising at least two heavy (H) chains and two light (L) chainsinter-connected by disulfide bonds. Each heavy chain is comprised of aheavy chain variable region (abbrebyted herein as V_(H)) and a heavychain constant region. The heavy chain constant region is comprised ofthree domains, CH1, CH2 and CH3. Each light chain is comprised of alight chain variable region (abbrebyted herein as V_(L)) and a lightchain constant region. The light chain constant region is comprised ofone domain, C_(L). The V_(H) and V_(L) regions can be further subdividedinto regions of hypervariability, termed complementarity determiningregions (CDR), interspersed with regions that are more conserved, termedframework regions (FR). Each V_(H) and V_(L) is, composed of three CDRsand four FRs arranged from amino-terminus to carboxy-terminus in thefollowing order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variableregions of the heavy and light chains contain a binding domain thatinteracts with an antigen. The constant regions of the antibodies maymediate the binding of the immunoglobulin to host tissues or factors,including various cells of the immune system (e.g., effector cells) andthe first component (Clq) of the classical complement system.

The term “antigen-binding portion” of an antibody (or simply “antigenportion”), as used herein, refers to one or more fragments of anantibody that retain the ability to specifically bind to an antigen(e.g., hTSLP). It has been shown that the antigen-binding function of anantibody can be performed by fragments of a full-length antibody.Examples of binding fragments encompassed within the term“antigen-binding portion” of an antibody include a Fab fragment, amonovalent fragment consisting of the V_(L), V_(H), C_(L) and CH1domains; a F(ab)₂ fragment, a bivalent fragment comprising two Fabfragments linked by a disulfide bridge at the hinge region; a Fdfragment consisting of the V_(H) and CH1 domains; a Fv fragmentconsisting of the V_(L) and V_(H) domains of a single arm of anantibody; a dAb fragment (Ward et al., 1989 Nature 341:544-546), whichconsists of a V_(H) domain; and an isolated complementarity determiningregion (CDR).

Furthermore, although the two domains of the Fv fragment, V_(L) andV_(H), are coded for by separate genes, they can be joined, usingrecombinant methods, by a synthetic linker that enables them to be madeas a single protein chain in which the V_(L) and V_(H) regions pair toform monovalent molecules (known as single chain Fv (scFv); see e.g.,Bird et al., 1988 Science 242:423-426; and Huston et al., 1988 Proc.Natl. Acad. Sci. 85:5879-5883). Such single chain antibodies are alsointended to be encompassed within the term “antigen-binding portion” ofan antibody. These antibody fragments are obtained using conventionaltechniques known to those of skill in the art, and the fragments arescreened for utility in the same manner as are intact antibodies.

An “isolated antibody”, as used herein, refers to an antibody that issubstantially free of other antibodies having different antigenicspecificities (e.g., an isolated antibody that specifically binds hTSLPis substantially free of antibodies that specifically bind antigensother than hTSLP). An isolated antibody that specifically binds hTSLPmay, however, have cross-reactivity to other antigens, such as TSLPmolecules from other species. Moreover, an isolated antibody may besubstantially free of other cellular material and/or chemicals.“Isolated antibody” also refers to an antibody to the target thatcross-reacts with known homologs/orthologs, as well as antibodies to thetarget that do not cross react with known homologs/orthologs.

The terms “monoclonal antibody” or “monoclonal antibody composition” asused herein refer to a preparation of antibody molecules of singlemolecular composition. A monoclonal antibody composition displays asingle binding specificity and affinity for a particular epitope.

The term “human antibody”, as used herein, is intended to includeantibodies having variable regions in which both the framework and CDRregions are derived from sequences of human origin. Furthermore, if theantibody contains a constant region, the constant region also is derivedfrom such human sequences, e.g., human germline sequences, or mutatedversions of human germline sequences. The human antibodies of theinvention may include amino acid residues not encoded by human sequences(e.g., mutations introduced by random or site-specific mutagenesis invitro or by somatic mutation in vivo). However, the term “humanantibody”, as used herein, is not intended to include antibodies inwhich CDR sequences derived from the germline of another mammalianspecies, such as a mouse, have been grafted onto human frameworksequences. CDR grafted antibodies, or alternative technology designed tominimize the Human Anti-murine Antibody response (humaneering technologyof Kalobios, or humanization technology of PDL). Xoma also has “humanengineering” technology; see e.g., U.S. Pat. No. 5,766,886.

The term “human monoclonal antibody” refers to refers to an antibodyobtained from a substantially homogeneous population of antibodies thatrecognizes and binds to a determinant (or epitope) on the antigen.Monoclonal antibodies displaying a single binding specificity which havevariable regions in which both the framework and CDR regions are derivedfrom human sequences. In one embodiment, the human monoclonal antibodiesare produced by a hybridoma which includes a B cell obtained from atransgenic nonhuman animal, e.g., a transgenic mouse, having a genomecomprising a human heavy chain transgene and a light chain transgenefused to an immortalized cell.

The term “recombinant human antibody”, as used herein, includes allhuman antibodies that are prepared, expressed, created or isolated byrecombinant means, such as antibodies isolated from an animal (e.g., amouse) that is transgenic or transchromosomal for human immunoglobulingenes or a hybridoma prepared therefrom, antibodies isolated from a hostcell transformed to express the human antibody, e.g., from atransfectoma, antibodies isolated from a recombinant, combinatorialhuman antibody library, and antibodies prepared, expressed, created orisolated by any other means that involve splicing of all or a portion ofa human immunoglobulin gene, sequences to other DNA sequences. Suchrecombinant human antibodies have variable regions in which theframework and CDR regions are derived from human germline immunoglobulinsequences. In certain embodiments, however, such recombinant humanantibodies can be subjected to in vitro mutagenesis (or, when an animaltransgenic for human Ig sequences is used, in vivo somatic mutagenesis)and thus the amino acid sequences of the V_(H) and V_(L) regions of therecombinant antibodies are sequences that, while derived from andrelated to human germline V_(H) and V_(L) sequences, may not naturallyexist within the human antibody germline repertoire in vivo.

As used herein, “isotype” refers to the antibody class (e.g., IgM, IgE,IgG such as IgG1, IgG2 or IgG4) that is encoded by the heavy chainconstant region genes.

The phrases “an antibody recognizing an antigen” and “an antibodyspecific for an antigen” are used interchangeably herein with the term“an antibody which binds specifically to an antigen.”

As used herein, an antibody that “specifically binds to hTSLP” isintended to refer to an antibody that binds to human TSLP with a K_(D)of 1×10⁻⁹ M or less. An antibody that “cross-reacts with an antigenother than hTSLP” is intended to refer to an antibody that binds thatantigen with a 1×10⁻⁹ M or less. An antibody that “does not cross-reactwith a particular antigen” is intended to refer to an antibody thatbinds to that antigen, with a K_(D) of 1.5×10⁻⁸ M or greater, or a K_(D)of 5−10×10⁻⁸M or 1×10⁻⁷ M or greater. In certain embodiments, suchantibodies that do not cross-react with the antigen exhibit essentiallyundetectable binding against these proteins in standard binding assays.

As used herein, an antibody that “inhibits binding of hTSLP to the hTSLPreceptor” refers to an antibody that inhibits hTSLP binding to thereceptor with a KD of 5 nM or less.

As used herein, an antibody that “inhibits inflammatory mediatorrelease” is intended to refer to an antibody that inhibits hTSLP inducedluciferase expression from a Baf-3 cell line transfected with theTSLP-receptor and a luciferase reporter system and hTSLP induced TARCsecretion from human primary monocytes isolated from PBMCs with an IC₅₀less than 1.0 nM.

The term “K_(assoc)” or “K_(a)”, as used herein, is intended to refer tothe association rate of a particular antibody-antigen interaction,whereas the term “K_(dis)” or “K_(D),” as used herein, is intended torefer to the dissociation rate of a particular antibody-antigeninteraction. The term “K_(D)”, as used herein, is intended to refer tothe dissociation constant, which is obtained from the ratio of K_(d) toK_(a) (i.e. K_(d)/K_(a)) and is expressed as a molar concentration (M).K_(D) values for antibodies can be determined using methods wellestablished in the art. A method for determining the K_(D) of anantibody is by using surface plasmon resonance, or using a biosensorsystem such as a Biacore® system.

As used herein, the term “high affinity” for an IgG antibody refers toan antibody having a K_(D) of 10⁻⁹ M or less for a target antigen.

As used herein, the term “subject” includes any human or nonhuman animal

The term “nonhuman animal” includes all vertebrates, e.g., mammals andnon-mammals, such as nonhuman primates, sheep, dogs, cats, horses, cowschickens, amphibians, reptiles, etc.

Various aspects of the invention are described in further detail in thefollowing subsections.

Standard assays to evaluate the binding ability of the antibodies towardhTSLP of various species are known in the art, including for example,ELISAs, western blots and RIAs. Suitable assays are described in detailin the Examples. The binding kinetics (e.g., binding affinity) of theantibodies also can be assessed by standard assays known in the art,such as by Biacore analysis. Assays to evaluate the effects of theantibodies on functional properties of hTSLP are described in furtherdetail in the Examples.

Accordingly, an antibody that “inhibits” one or more of these hTSLPfunctional properties (e.g., biochemical, immunochemical, cellular,physiological or other biological activities, or the like) as determinedaccording to methodologies known to the art and described herein, willbe understood to relate to a statistically significant decrease in theparticular activity relative to that seen in the absence of the antibody(e.g., or when a control antibody of irrelevant specificity is present).An antibody that inhibits hTSLP activity effects such a statisticallysignificant decrease by at least 10% of the measured parameter, by atleast 50%, 80% or 90%, and in certain embodiments an antibody of theinvention may inhibit greater than 95%, 98% or 99% of hTSLP functionalactivity.

Monoclonal Antibodies

Antibodies of the invention are the human monoclonal antibodies,isolated and structurally characterized as described, in Examples 1-5.The V_(H) amino acid sequences of the antibodies are shown in SEQ IDNOs: 1-31 respectively. The V_(L) amino acid sequences of the antibodiesare shown in SEQ ID NOs: 32-66 respectively. Other antibodies of theinvention include amino acids that have been mutated, yet have at least60, 70, 80, 90 or 95 percent identity in the CDR regions with the CDRregions depicted in the sequences described above.

Since each of these antibodies can bind to hTSLP, the V_(H) and V_(L)sequences can be “mixed and matched” to create other anti-hTSLP bindingmolecules of the invention. hTSLP binding of such “mixed and matched”antibodies can be tested using the binding assays described above and inthe Examples (e.g., ELISAs). When V_(H) and V_(L) chains are mixed andmatched, a V_(H) sequence from a particular V_(H)/V_(L) pairing shouldbe replaced with a structurally similar V_(H) sequence. Likewise, aV_(L) sequence from a particular V_(H)/V_(L) pairing should be replacedwith a structurally similar V_(L) sequence. The V_(H) and V_(L)sequences of the antibodies of the present invention are particularlyamenable for mixing and matching, since these antibodies use V_(H) andV_(L) sequences derived from the same germline sequences and thusexhibit structural similarity.

In another aspect, the invention provides antibodies that comprise theheavy chain and light chain CDR1s, CDR2s and CDR3s of the antibodies, orcombinations thereof. The amino acid sequences of the V_(H) CDR1s of theantibodies are shown in SEQ ID NOs: 1-7. The amino acid sequences of theV_(H) CDR2s of the antibodies and are shown in SEQ ID NOs: 8-25. Theamino acid sequences of the V_(H) CDR3s of the antibodies are shown inSEQ ID NOs: 26-31. The amino acid sequences of the V_(L) CDR1s of theantibodies are shown in SEQ ID NOs: 32-40. The amino acid sequences ofthe V_(L) CDR2s of the antibodies are shown in SEQ ID NOs: 41-49. Theamino acid sequences of the V_(L) CDR3s of the antibodies are shown inSEQ ID NOs: 50-66. The CDR regions are delineated using the Kabat system(Kabat, E. A., et al., 1991 Sequences of Proteins of ImmunologicalInterest, Fifth Edition, U.S. Department of Health and Human Services,NIH Publication No. 91-3242).

Given that each of these antibodies can bind to hTSLP and thatantigen-binding specificity is provided primarily by the CDR1, 2 and 3regions, the V_(H) CDR1, 2 and 3 sequences and V_(L) CDR1, 2 and 3sequences can be “mixed and matched” (i.e., CDRs from differentantibodies can be mixed and match, although each antibody must contain aV_(H) CDR1, 2 and 3 and a V_(L) CDR1, 2 and 3) to create otheranti-hTSLP binding molecules of the invention. hTSLP binding of such“mixed and matched” antibodies can be tested using the binding assaysdescribed above and in the Examples (e.g., ELISAs). When V_(H) CDRsequences are mixed and matched, the CDR1, CDR2 and/or CDR3 sequencefrom a particular V_(H) sequence should be replaced with a structurallysimilar CDR sequence(s). Likewise, when V_(L) CDR sequences are mixedand matched, the CDR1, CDR2 and/or CDR3 sequence from a particular V_(L)sequence should be replaced with a structurally similar CDR sequence(s).It will be readily apparent to the ordinarily skilled artisan that novelV_(H) and V_(L) sequences can be created by substituting one or moreV_(H) and/or V_(L) CDR region sequences with structurally similarsequences from the CDR sequences shown herein for monoclonal antibodiesof the present invention.

An isolated monoclonal antibody, or antigen binding portion thereof has:a heavy chain variable region CDR1 comprising an amino acid sequenceselected from the group consisting of SEQ ID NOs: 1-7; a heavy chainvariable region CDR2 comprising an amino acid sequence selected from thegroup consisting of SEQ ID NOs: 8-25; a heavy chain variable region CDR3comprising an amino acid sequence selected from the group consisting ofSEQ ID NOs: 26-31; a light chain variable region CDR1 comprising anamino acid sequence selected from the group consisting of SEQ ID NOs:32-40; a light chain variable region CDR2 comprising an amino acidsequence selected from the group consisting of SEQ ID NOs: 41-49; and alight chain variable region CDR3 comprising an amino acid sequenceselected from the group consisting of SEQ ID NOs: 50-66; wherein theantibody specifically binds hTSLP.

In a certain embodiment, the antibody consists of: a heavy chainvariable region CDR1 comprising SEQ ID NO: 3; a heavy chain variableregion CDR2 comprising SEQ ID NO: 15; a heavy chain variable region CDR3comprising SEQ ID NO: 28; a light chain variable region CDR1 comprisingSEQ ID NO: 38; a light chain variable region CDR2 comprising SEQ ID NO:47; and a light chain variable region CDR3 comprising SEQ ID NO: 60.

In another embodiment, the antibody consists of: a heavy chain variableregion CDR1 comprising SEQ ID NO: 3; a heavy chain variable region CDR2comprising SEQ ID NO:17; a heavy chain variable region CDR3 comprisingSEQ ID NO: 28; a light chain variable region CDR1 comprising SEQ ID NO:38; a light chain variable region CDR2 comprising SEQ ID NO: 47; and alight chain variable region CDR3 comprising SEQ ID NO: 60.

In yet another embodiment, the antibody consists of: a heavy chainvariable region CDR1 comprising SEQ ID NO: 3; a heavy chain variableregion CDR2 comprising SEQ ID NO: 18; a heavy chain variable region CDR3comprising SEQ ID NO: 28; a light chain variable region CDR1 comprisingSEQ ID NO: 38; a light chain variable region CDR2 comprising SEQ ID NO:47; and a light chain variable region CDR3 comprising SEQ ID NO: 60.

In another embodiment, the antibody consists of: a heavy chain variableregion CDR1 comprising SEQ ID NO: 3; a heavy chain variable region CDR2comprising SEQ ID NO: 19; a heavy chain variable region CDR3 comprisingSEQ ID NO: 28; a light chain variable region CDR1 comprising SEQ ID NO:38; a light chain variable region CDR2 comprising SEQ ID NO: 47; and alight chain variable region CDR3 comprising SEQ ID NO: 60.

In another embodiment, the antibody consists of: a heavy chain variableregion CDR1 comprising SEQ ID NO: 3; a heavy chain variable region CDR2comprising SEQ ID NO: 20; a heavy chain variable region CDR3 comprisingSEQ ID NO: 28; a light chain variable region CDR1 comprising SEQ ID NO:38; a light chain variable region CDR2 comprising SEQ ID NO: 47; and alight chain variable region CDR3 comprising SEQ ID NO: 60.

As used herein, a human antibody comprises heavy or light chain variableregions that is “the product of” or “derived from” a particular germlinesequence if the variable regions of the antibody are obtained from asystem that uses human germline immunoglobulin genes. Such systemsinclude immunizing a transgenic mouse carrying human immunoglobulingenes with the antigen of interest or screening a human immunoglobulingene library displayed on phage with the antigen of interest. A humanantibody that is “the product of” or “derived from” a human germlineimmunoglobulin sequence can be identified as such by comparing the aminoacid sequence of the human antibody to the amino acid sequences of humangermline immunoglobulins and selecting the human germline immunoglobulinsequence that is closest in sequence (i.e., greatest % identity) to thesequence of the human antibody. A human antibody that is “the productof” or “derived from” a particular human germline immunoglobulinsequence may contain amino acid differences as compared to the germlinesequence, due to, for example, naturally occurring somatic mutations orintentional introduction of site-directed mutation. However, a selectedhuman antibody typically is at least 90% identical in amino acidssequence to an amino acid sequence encoded by a human germlineimmunoglobulin gene and contains amino acid residues that identify thehuman antibody as being human when compared to the germlineimmunoglobulin amino acid sequences of other species (e.g., murinegermline sequences). In certain cases, a human antibody may be at least60%, 70%, 80%, 90%, or at least 95%, or even at least 96%, 97%, 98%, or99% identical in amino acid sequence to the amino acid sequence encodedby the germline immunoglobulin gene. Typically, a human antibody derivedfrom a particular human germline sequence will display no more than 10amino acid differences from the amino acid sequence encoded by the humangermline immunoglobulin gene. In certain cases, the human antibody maydisplay no more than 5, or even no more than 4, 3, 2, or 1 amino aciddifference from the amino acid sequence encoded by the gennlineimmunoglobulin gene.

Homologous Antibodies

In yet another embodiment, an antibody of the invention has heavy andlight chain variable regions having amino acid sequences that arehomologous to the amino acid sequences of the antibodies describedherein, and wherein the antibodies retain the desired functionalproperties of the anti-hTSLP antibodies of the Invention.

For example, the invention provides an isolated monoclonal antibody, orantigen binding portion thereof, comprising a heavy chain variableregion and a light chain variable region, wherein: the heavy chainvariable region comprises an amino acid sequence that is at least 80%homologous to an amino acid sequence selected from the group consistingof SEQ ID NOs: 1-31; the light chain variable region comprises an aminoacid sequence that is at least 80% homologous to an amino acid sequenceselected from the group consisting of SEQ ID NOs: 32-66; the antibodyspecifically binds to hTSLP, and the antibody exhibits at least one ofthe following functional properties: the antibody inhibits binding hTSLPprotein to the hTSLP receptor or the antibody inhibits hTSLP receptorbinding preventing or ameliorating an inflammatory or allergiccondition, particularly an inflammatory or obstructive airways disease,or the antibody inhibits hTSLP receptor binding preventing orameliorating asthma or the antibody inhibits hTSLP receptor bindingpreventing or ameliorating COPD.

In various embodiments, the antibody may exhibit one or more, two ormore, or three of the functional properties discussed above. Theantibody can be, for example, a human antibody, a humanized antibody ora chimeric antibody.

In other embodiments, the V_(H) and/or V_(L) amino acid sequences may be60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% homologous to thesequences set forth above. An antibody having V_(H) and V_(L) regionshaving high (i.e., 80% or greater) homology to the V_(H) and V_(L)regions of SEQ ID NOs: 1-31 and 32-66 respectively, can be obtained bymutagenesis (e.g., site-directed or PCR-mediated mutagenesis) of nucleicacid molecules encoding SEQ ID NOs: 1-31 and/or 32-66, followed bytesting of the encoded altered antibody for retained function (i.e., thefunctions set forth above) using the functional assays described herein.

As used herein, the percent homology between two amino acid sequences isequivalent to the percent identity between the two sequences. Thepercent identity between the two sequences is a function of the numberof identical positions shared by the sequences (i.e., % homology=# ofidentical positions/total # of positions×100), taking into account thenumber of gaps, and the length of each gap, which need to be introducedfor optimal alignment of the two sequences. The comparison of sequencesand determination of percent identity between two sequences can beaccomplished using a mathematical algorithm, as described in thenon-limiting examples below.

The percent identity between two amino acid sequences can be determinedusing the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci.,4:11-17, 1988) which has been incorporated into the ALIGN program(version 2.0), using a PAM120 weight residue table, a gap length penaltyof 12 and a gap penalty of 4. In addition, the percent identity betweentwo amino acid sequences can be determined using the Needleman andWunsch (J. Mol, Biol. 48:444-453, 1970) algorithm which has beenincorporated into the GAP program in the GCG software package (availableat http://www.gcg.com), using either a Blossom 62 matrix or a PAM250matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a lengthweight of 1, 2, 3, 4, 5, or 6.

Additionally or alternatively, the protein sequences of the presentinvention can further be used as a “query sequence” to perform a searchagainst public databases to, for example, identify related sequences.Such searches can be performed using the XBLAST program (version 2.0) ofAltschul, et al., 1990 J. Mol. Biol. 215:403-10. BLAST protein searchescan be performed with the XBLAST program, score=50, wordlength=3 toobtain amino acid sequences homologous to the antibody molecules of theinvention. To obtain gapped alignments for comparison purposes, GappedBLAST can be utilized as described in Altschul et al., 1997 NucleicAcids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLASTprograms, the default parameters of the respective programs (e.g.,XBLAST and NBLAST) can be used. See http:www.ncbi.nlm.nih.gov.

Antibodies with Conservative Modifications

In certain embodiments, an antibody of the invention has a heavy chainvariable region consist of CDR1, CDR2, and CDR3 sequences and a lightchain variable region consisting of CDR1, CDR2, and CDR3 sequences,wherein one or more of these CDR sequences have specified amino acidsequences based on the antibodies described herein or conservativemodifications thereof, and wherein the antibodies retain the desiredfunctional properties of the anti-hTSLP antibodies of the invention.Accordingly, the invention provides an isolated monoclonal antibody, orantigen binding portion thereof, consisting of a heavy chain variableregion consisting of CDR1, CDR2, and CDR3 sequences and a light chainvariable region consisting of CDR1, CDR2, and CDR3 sequences, wherein:the heavy chain variable regions of CDR1 is sequences consisting ofamino acid sequences selected from the group consisting of amino acidsequences of SEQ ID NOs: 1-7, and conservative modifications thereof;the heavy chain variable region of CDR2 is sequences consisting of aminoacid sequences selected from the group consisting of amino acidsequences of SEQ ID NOs: 8-25, and conservative modifications thereof;the heavy chain variable region of CDR3 is sequences consisting of aminoacid sequences selected from the group consisting of amino acidsequences of SEQ ID NOs: 26-31, and conservative modifications thereof;the light chain variable regions of CDR1 is sequences consisting ofamino acid sequences selected from the group consisting of amino acidsequences of SEQ ID NOs: 32-40, and conservative modifications thereof;the light chain variable regions of CDR2 is sequences consisting ofamino acid sequences selected from the group consisting of amino acidsequences of SEQ ID NOs: 41-49, and conservative modifications thereof;the light chain variable regions of CDR3 is sequences consisting ofamino acid sequences selected from the group consisting of amino acidsequences of SEQ ID NOs: 50-66, and conservative modifications thereof;the antibody specifically binds to hTSLP; and the antibody inhibitshTSLP receptor binding preventing inflammatory mediator release.

In various embodiments, the antibody may exhibit one or more, two ormore, or three or more of the functional properties listed discussedabove. Such antibodies can be, for example, human antibodies, humanizedantibodies or chimeric antibodies.

As used herein, the term “conservative sequence modifications” isintended to refer to amino acid modifications that do not significantlyaffect or alter the binding characteristics of the antibody containingthe amino acid sequence. Such conservative modifications include aminoacid substitutions, additions and deletions. Modifications can beintroduced into an antibody of the invention by standard techniquesknown in the art, such as site-directed mutagenesis and PCR-mediatedmutagenesis.

Conservative amino acid substitutions are ones in which the amino acidresidue is replaced with an amino acid residue having a similar sidechain. Families of amino acid residues having similar side chains havebeen defined in the art. These families include amino acids with basicside chains (e.g., lysine, arginine, histidine), acidic side chains(e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g.,glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine,tryptophan), nonpolar side chains (e.g., alanine, valine, leucine,isoleucine, proline, phenylalanine, methionine), beta-branched sidechains (e.g., threonine, valine, isoleucine) and aromatic side chains(e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one ormore amino acid residues within the CDR regions of an antibody of theinvention can be replaced with other amino acid residues from the sameside chain family, and the altered antibody can be tested for retainedfunction using the functional assays described herein.

Antibodies that Bind to the Same Epitope as Anti-hTSLP Antibodies of theInvention

In another embodiment, the invention provides antibodies that bind tothe same epitope as do the various anti-hTSLP antibodies of theinvention provided herein. Such additional antibodies can be identifiedbased on their ability to cross-compete (e.g., to competitively inhibitthe binding of, in a statistically significant manner) with otherantibodies of the invention in standard hTSLP binding assays. Theability of a test antibody to inhibit the binding of antibodies of thepresent invention to human hTSLP demonstrates that the test antibody cancompete with that antibody for binding to hTSLP; such an antibody may,according to non-limiting theory, bind to the same or a related (e.g., astructurally similar or spatially proximal) epitope on hTSLP as theantibody with which it competes. In a certain embodiment, the antibodythat binds to the same epitope on hTSLP as the antibodies of the presentinvention is a human monoclonal antibody. Such human monoclonalantibodies can be prepared and isolated as described in the Examples.

Engineered and Modified Antibodies

An antibody of the invention further can be prepared using an antibodyhaving one or more of the V_(H) and/or V_(L) sequences shown herein asstarting material to engineer a modified antibody, which modifiedantibody may have altered properties from the starting antibody. Anantibody can be engineered by modifying one or more residues within oneor both variable regions (i.e., V_(H) and/or V_(L)), for example withinone or more CDR regions and/or within one or more framework regions.Additionally or alternatively, an antibody can be engineered bymodifying residues within the constant region(s), for example to alterthe effector function(s) of the antibody.

One type of variable region engineering that can be performed is CDRgrafting. Antibodies interact with target antigens predominantly throughamino acid residues that are located in the six heavy and light chaincomplementarity determining regions (CDRs). For this reason, the aminoacid sequences within CDRs are more diverse between individualantibodies than sequences outside of CDRs. Because CDR sequences areresponsible for most antibody-antigen interactions, it is possible toexpress recombinant antibodies that mimic the properties of specificnaturally occurring antibodies by constructing expression vectors thatinclude CDR sequences from the specific naturally occurring antibodygrafted onto framework sequences from a different antibody withdifferent properties (see, e.g., Riechmann, L. et al., 1998 Nature332:323-327; Jones, P. et al., 1986 Nature 321:522-525; Queen, C. etal., 1989 Proc. Natl. Acad. See. U.S.A. 86:10029-10033; U.S. Pat. No.5,225,539 to winter, and U.S. Pat. Nos. 5,530,101; 5,585,089; 5,693,762and 6,180,370 to Queen et al.)

Accordingly, another embodiment of the invention pertains to an isolatedmonoclonal antibody, or antigen binding portion thereof, comprising aheavy chain variable region comprising CDR1 sequences having an aminoacid sequence selected from the group consisting of SEQ ID NOs: 1-7;CDR2 sequences having an amino acid sequence selected from the groupconsisting of SEQ ID NOs: 8-25; CDR3 sequences having an amino acidsequence selected from the group consisting of SEQ ID NOs: 26-31,respectively; and a light chain variable region having CDR1 sequenceshaving an amino acid sequence selected from the group consisting of SEQID NOs: 32-40; CDR2 sequences having an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 41-49; and CDR3 sequencesconsisting of an amino acid sequence selected from the group consistingof SEQ ID NOs: 50-66, respectively. Thus, such antibodies contain theV_(H) and V_(L) CDR sequences of monoclonal antibodies, yet may containdifferent framework sequences from these antibodies.

Such framework sequences can be obtained from public DNA databases orpublished references that include germline antibody gene sequences. Forexample, germline DNA sequences for human heavy and light chain variableregion genes can be found in the “VBase” human germline sequencedatabase (available on the Internet at www.mrc-cpe.cam.ac.uk/vbase), aswell as in Kabat, E. A., et al., 1991 Sequences of Proteins ofImmunological Interest, Fifth Edition, U.S. Department of Health andHuman Services, NIH Publication No. 91-3242; Tomlinson, I. M., et al.,1992 J. fol. Biol. 227:776-798; and Cox, J. P. L. et al., 1994 Eur. JImmunol. 24:827-836; the contents of each of which are expresslyincorporated herein by reference.

An example of framework sequences for use in the antibodies of theinvention are those that are structurally similar to the frameworksequences used by selected antibodies of the invention, e.g., consensussequences and/or framework sequences used by monoclonal antibodies ofthe invention. The V_(H) CDR1, 2 and 3 sequences, and the V_(L) CDR1, 2and 3 sequences, can be grafted onto framework regions that have theidentical sequence as that found in the germline immunoglobulin genefrom which the framework sequence derive, or the CDR sequences can begrafted onto framework regions that contain one or more mutations ascompared to the germline sequences. For example, it has been found thatin certain instances it is beneficial to mutate residues within theframework regions to maintain or enhance the antigen binding ability ofthe antibody (see e.g., U.S. Pat. Nos. 5,530,101; 5,585,089; 5,693,762and 6,180,370 to Queen et al).

Another type of variable region modification is to mutate amino acidresidues within the V_(H) and/or V_(L) CDR1, CDR2 and/or CDR3 regions tothereby improve one or more binding properties (e.g., affinity) of theantibody of interest, known as “affinity maturation.” Site-directedmutagenesis or PCR-mediated mutagenesis can be performed to introducethe mutation(s) and the effect on antibody binding, or other functionalproperty of interest, can be evaluated in in vitro or in vivo assays asdescribed herein and provided in the Examples. Conservativemodifications (as discussed above) can be introduced. The mutations maybe amino acid substitutions, additions or deletions. Moreover, typicallyno more than one, two, three, four or five residues within a CDR regionare altered.

Accordingly, in another embodiment, the invention provides isolatedanti-hTSLP monoclonal antibodies, or antigen binding portions thereof,consisting of a heavy chain variable region having: a V_(H) CDR1 regionconsisting of an amino acid sequence selected from the group having SEQID NOs: 1-7 or an amino acid sequence having one, two, three, four orfive amino acid substitutions, deletions or additions as compared to SEQID NOs: 1-7; a V_(H) CDR2 region having an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 8-25, or an amino acid sequencehaving one, two, three, four or five amino acid substitutions, deletionsor additions as compared to SEQ ID NOs: 8-25; a V_(H) CDR3 region havingan amino acid sequence selected from the group consisting of SEQ ID NOs:26-31, or an amino acid sequence having one, two, three, four or fiveamino acid substitutions, deletions or additions as compared to SEQ IDNOs: 26-31; a V_(L) CDR1 region having an amino acid sequence selectedfrom the group consisting of SEQ ID NOs: 32-40, or an amino acidsequence having one, two, three, four or five amino acid substitutions,deletions or additions as compared to SEQ ID NOs: 32-40; a V_(L) CDR2region having an amino acid sequence selected from the group consistingof SEQ ID NOs: 41-49, or an amino acid sequence having one, two, three,four or five amino acid substitutions, deletions or additions ascompared to SEQ ID NOs: 41-49; and a V_(L) CDR3 region having an aminoacid sequence selected from the group consisting of SEQ ID NOs: 50-66,or an amino acid sequence having one, two, three, four or five aminoacid substitutions, deletions or additions as compared to SEQ ID NOs:50-66.

Engineered antibodies of the invention include those in whichmodifications have been made to framework residues within V_(H) and/orV_(L), e.g. to improve the properties of the antibody. Typically suchframework modifications are made to decrease the immunogenicity of theantibody. For example, one approach is to “backmutate” one or moreframework residues to the corresponding germline sequence. Morespecifically, an antibody that has undergone somatic mutation maycontain framework residues that differ from the germline sequence fromwhich the antibody is derived. Such residues can be identified bycomparing the antibody framework sequences to the germline sequencesfrom which the antibody is derived. To return the framework regionsequences to their germline configuration, the somatic mutations can be“backmutated” to the germline sequence by, for example, site-directedmutagenesis or PCR-mediated mutagenesis. Such “backmutated” antibodiesare also intended to be encompassed by the invention.

Another type of framework modification involves mutating one or moreresidues within the framework region, or even within one or more CDRregions, to remove T cell—epitopes to thereby reduce the potentialimmunogenicity of the antibody. This approach is also referred to as“deimmunization” and is described in further detail in U.S. PatentPublication No. 20030153043 by Carr et al.

In addition or alternative to modifications made within the framework orCDR regions, antibodies of the invention may be engineered to includemodifications within the Fc region, typically to alter one or morefunctional properties of the antibody, such as serum half-life,complement fixation, Fc receptor binding, and/or antigen-dependentcellular cytotoxicity. Furthermore, an antibody of the invention may bechemically modified (e.g., one or more chemical moieties can be attachedto the antibody) or be modified to alter its glycosylation, again toalter one or more functional properties of the antibody. Each of theseembodiments is described in further detail below. The numbering ofresidues in the Fc region is that of the EU index of Kabat.

In one embodiment, the hinge region of CH1 is modified such that thenumber of cysteine residues in the hinge region is altered, e.g.,increased or decreased. This approach is described further in U.S. Pat.No. 5,677,425 by Bodmer et al. The number of cysteine residues in thehinge region of CH1 is altered to, for example, facilitate assembly ofthe light and heavy chains or to increase or decrease the stability ofthe antibody.

In another embodiment, the Fc hinge region of an antibody is mutated todecrease the biological half-life of the antibody. More specifically,one or more amino acid mutations are introduced into the CH2-CH3 domaininterface region of the Fc-hinge fragment such that the antibody hasimpaired Staphylococcyl protein A (SpA) binding relative to nativeFc-hinge domain SpA binding. This approach is described in furtherdetail in U.S. Pat. No. 6,165,745 by Ward et al.

In another embodiment, the antibody is modified to increase itsbiological half-life. Various approaches are possible. For example, oneor more of the following mutations can be introduced: T252L, T254S,T256F, as described in U.S. Pat. No. 6,277,375 to Ward. Alternatively,to increase the biological half life, the antibody can be altered withinthe CH1 or CL region to contain a salvage receptor binding epitope takenfrom two loops of a CH2 domain of an Fc region of an IgG, as describedin U.S. Pat. Nos. 5,869,046 and 6,121,022 by Presta et al. The Fcconstant region of an antibody is critical for determining serumhalf-life and effector functions, i.e., antibody dependent cellcytotoxicity (ADCC) or complement dependent cytotoxicity (CDC)activities. One can engineer specific mutants of the Fc fragment toalter the effector function and/or serum half-life (see Xencortechnology for example) (See e.g., WO2004029207).

One method to alter effector function and serum half-life of an antibodyis to graft the variable region of an antibody fragment with an Fcfragment having the appropriate effector function. IgG1 or IgG4 isotypescan be selected for cell killing activity, whereas IgG2 isotype can beused for silent antibodies (with no cell killing activity).

Silent antibodies with long serum half-life can be obtained by makingchimeric fusion of variable regions of an antibody with a serum proteinsuch as HSA or a protein binding to such serum protein, such HSA-bindingprotein.

In yet other embodiments, the Fc region is altered by replacing at leastone amino acid residue with a different amino acid residue to alter theeffector functions of the antibody. For example, one or more amino acidscan be replaced with a different amino acid residue such that theantibody has an altered affinity for an effector ligand but retains theantigen-binding ability of the parent antibody. The effector ligand towhich affinity is altered can be, for example, an Fc receptor or the C1component of complement. This approach is described in further detail inU.S. Pat. Nos. 5,624,821 and 5,648,260, both by Winter et al.

In another embodiment, one or more amino acids selected from amino acidresidues can be replaced with a different amino acid residue such thatthe antibody has altered C1q binding and/or reduced or abolishedcomplement dependent cytotoxicity (CDC). This approach is described infurther detail in U.S. Pat. No. 6,194,551 by Idusogie et at.

In another embodiment, one or more amino acid residues are altered tothereby alter the ability of the antibody to fix complement. Thisapproach is described further in PCT Publication WO 94/29351 by Bodmeret al.

In yet another embodiment, the Fc region is modified to increase theability of the antibody to mediate antibody dependent cellularcytotoxicity (ADCC) and/or to increase the affinity of the antibody foran Fey receptor by modifying one or more amino acids. This approach isdescribed further in PCT Publication WO 00/42072 by Presta. Moreover,the binding sites on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn havebeen mapped and variants with improved binding have been described (seeShields, R. L. et al., 2001 J. Biol. Chen. 276:6591-6604).

In still another embodiment, the glycosylation of an antibody ismodified. For example, an aglycoslated antibody can be made (i.e., theantibody lacks glycosylation). Glycosylation can be altered to, forexample, increase the affinity of the antibody for “antigen”. Suchcarbohydrate modifications can be accomplished by; for example, alteringone or more sites of glycosylation within the antibody sequence. Forexample, one or more amino acid substitutions can be made that result inelimination of one or more variable region framework glycosylation sitesto thereby eliminate glycosylation at that site. Such aglycosylation mayincrease the affinity of the antibody for antigen. Such an approach isdescribed in further detail in U.S. Pat. Nos. 5,714,350 and 6,350,861 byCo et al.

Additionally or alternatively, an antibody can be made that has analtered type of glycosylation, such as a hypofucosylated antibody havingreduced amounts of fucosyl residues or an antibody having increasedbisecting GlcNac structures. Such altered glycosylation patterns havebeen demonstrated to increase the ADCC ability of antibodies. Suchcarbohydrate modifications can be accomplished by, for example,expressing the antibody in a host cell with altered glycosylationmachinery. Cells with altered glycosylation machinery have beendescribed in the art and can be used as host cells in which to expressrecombinant antibodies of the invention to thereby produce an antibodywith altered glycosylation. For example, EP 1,176,195 by Hang et al.describes a cell line with a functionally disrupted FUT8 gene, whichencodes a fucosyl transferase, such that antibodies expressed in such acell line exhibit hypofucosylation. PCT Publication WO 03/035835 byPresta describes a variant CHO cell line, Lecl3 cells, with reducedability to attach fucose to Asn(297)-linked carbohydrates, alsoresulting in hypofucosylation of antibodies expressed in that host cell(see also Shields, R. L. et al., 2002 J. Biol. Chem. 277:26733-26740).PCT Publication WO 99/54342 by Umana et al. describes cell linesengineered to express glycoprotein-modifying glycosyl transferases(e.g., beta(1,4)-N acetylglucosaminyltransferase III (GnTIII)) such thatantibodies expressed in the engineered cell lines exhibit increasedbisecting GlcNac structures which results in increased ADCC activity ofthe antibodies (see also Umana et al., 1999 Nat. Biotech. 17:176-180).

Another modification of the antibodies herein that is contemplated bythe invention is pegylation. An antibody can be pegylated to, forexample, increase the biological (e.g., serum) half-life of theantibody. To pegylate an antibody, the antibody, or fragment thereof,typically is reacted with polyethylene glycol (PEG), such as a reactiveester or aldehyde derivative of PEG, under conditions in which one ormore PEG groups become attached to the antibody or antibody fragment.The pegylation can be carried out by an acylation reaction or analkylation reaction with a reactive PEG molecule (or an analogousreactive water-soluble polymer). As used herein, the term “polyethyleneglycol” is intended to encompass any of the forms of PEG that have beenused to derivatize other proteins, such as mono (C1-C10) alkoxy- oraryloxy-polyethylene glycol or polyethylene glycol-maleimide. In certainembodiments, the antibody to be pegylated is an aglycosylated antibody.Methods for pegylating proteins are known in the art and can be appliedto the antibodies of the invention. See for example, EP 0 154 316 byNishimura et al. and EP 0 401 384 by Ishikawa et al.

Effector functions can also be altered by modulating the glycosylationpattern of the antibody. Glycart (e.g., U.S. Pat. No. 6,602,684), Biowa(e.g., U.S. Pat. No. 6,946,292) and Genentech (e.g WO03/035835) haveengineered mammalian cell lines to produce antibodies with increased ordecreased effector function. Especially, non fucosylated antibodies willhave enhanced ADCC activities. Glycofi has also developed yeast celllines capable of producing specific glycoforms of antibodies. Also KyowaHakka/Biowa technology to reduce fucose. See, e.g., WO 03/085102.

A wide variety of antibody/immunoglobulin frameworks or scaffolds can beemployed so long as the resulting polypeptide includes one or morebinding region which is specific for the hTSLP protein. Such frameworksor scaffolds include the 5 main idiotypes of human immunoglobulins, orfragments thereof (such as those disclosed elsewhere herein), andinclude immunoglobulins of other animal species, preferably havinghumanized aspects. Single heavy-chain antibodies such as thoseidentified in camelids are of particular interest in this regard. Novelframeworks, scaffolds and fragments continue to be discovered anddeveloped by those skilled in the art.

Alternatively, known or future non-immunoglobulin frameworks andscaffolds may be employed, as long as they comprise a binding regionspecific for the hTSLP protein. Such compounds are known herein as“polypeptides comprising a cMAC-specific binding region”. Knownnon-immunoglobulin frameworks or scaffolds include Adnectins(fibronectin) (Compound Therapeutics, Inc., Waltham, Mass.), ankyrin(Molecular Partners AG, Zurich, Switzerland), domain antibodies(Domantis, Ltd (Cambridge, Mass.) and Ablynx nv (Zwijnaarde, Belgium)),lipocalin (Anticalin) (Pieris Proteolab AG, Freising, Germany), smallmodular immuno-pharmaceuticals (Trubion Pharmaceuticals Inc., Seattle,Wash.), maxybodies (Avidia, Inc. (Mountain View, Calif.)), Protein A(Affibody AG, Sweden) and affilin (gamma-crystallin or ubiquitin) (ScilProteins GmbH, Halle, Germany).

According to the instant invention, the anti-hTSLP antibody or fragmentthereof, or the polypeptide comprising a hTSLP-specific binding region,regardless of the framework or scaffold employed, may be bound, eithercovalently or non-covalently, to an additional moiety. The additionalmoiety may be a polypeptide, an inert polymer such as PEG, smallmolecule, radioisotope, metal, ion, nucleic acid or other type ofbiologically relevant molecule. Such a construct, which may be known asan immunoconjugate, immunotoxin, or the like, is also included in themeaning of antibody, antibody fragment or polypeptide comprisingahTSLP-specific binding region, as used herein.

Methods of Engineering Antibodies

As discussed above, the anti-hTSLP antibodies having V_(H) and V_(L)sequences shown herein can be used to create new anti-hTSLP antibodiesby modifying the V_(H) and/or V_(L) sequences, or the constant region(s)attached thereto. Thus, in another aspect of the invention, thestructural features of an anti-hTSLP antibody of the invention are usedto create structurally related anti-hTSLP antibodies that retain atleast one functional property of the antibodies of the invention, suchas binding to hTSLP and also inhibiting one or more functionalproperties of hTSLP (e.g., receptor binding, inhibition of mediatorrelease).

For example, one or more CDR regions of the antibodies of the presentinvention, or mutations thereof, can be combined recombinantly withknown framework regions and/or other CDRs to create additional,recombinantly-engineered, anti-hTSLP antibodies of the invention, asdiscussed above. Other types of modifications include those described inthe previous section. The starting material for the engineering methodis one or more of the V_(H) and/or V_(L) sequences provided herein, orone or more CDR regions thereof. To create the engineered antibody, itis not necessary to actually prepare (i.e., express as a protein) anantibody having one or more of the V_(H) and/or V_(L) sequences providedherein, or one or more CDR regions thereof. Rather, the informationcontained in the sequence(s) is used as the starting material to createa “second generation” sequence(s) derived from the original sequence(s)and then the “second generation” sequence(s) is prepared and expressedas a protein.

Accordingly, in another embodiment, the invention provides a method forpreparing an anti-hTSLP antibody consisting of: a heavy chain variableregion antibody sequence having a CDR1 sequence selected from the groupconsisting of SEQ ID NOs: 1-7, a CDR2 sequence selected from the groupconsisting of SEQ ID NOs: 8-25 and/or a CDR3 sequence selected from thegroup consisting of SEQ ID NOs: 26-31 and a light chain variable regionantibody sequence having a CDR1 sequence selected from the groupconsisting of SEQ ID NOs: 32-40, a CDR2 sequence selected from the groupconsisting of SEQ ID NOs: 41-49 and/or a CDR3 sequence selected from thegroup consisting of SEQ ID NOs: 50-66; altering at least one amino acidresidue within the heavy chain variable region antibody sequence and/orthe light chain variable region antibody sequence to create at least onealtered antibody sequence; and expressing the altered antibody sequenceas a protein.

Standard molecular biology techniques can be used to prepare and expressthe altered antibody sequence. The antibody encoded by the alteredantibody sequence(s) is one that retains one, some or all of thefunctional properties of the anti-hTSLP antibodies described herein,which functional properties include, but are not limited to,specifically binding to hTSLP; and the antibody exhibits at least one ofthe following functional properties: the antibody inhibits binding ofhTSLP protein to the hTSLP receptor, or the antibody inhibits hTSLPreceptor binding preventing or ameliorating an inflammatory, fibrotic orallergic condition, particularly an inflammatory or obstructive airwaysdisease, or the antibody inhibits hTSLP receptor binding therebypreventing or ameliorating asthma.

The altered antibody may exhibit one or more, two or more, or three ormore of the functional properties discussed above.

The functional properties of the altered antibodies can be assessedusing standard assays available in the art and/or described herein, suchas those set forth in the Examples (e.g., ELISAs).

In certain embodiments of the methods of engineering antibodies of theinvention, mutations can be introduced randomly or selectively along allor part of an anti-hTSLP antibody coding sequence and the resultingmodified anti-hTSLP antibodies can be screened for binding activityand/or other functional properties as described herein. Mutationalmethods have been described in the art. For example, PCT Publication WO02/092780 by Short describes methods for creating and screening antibodymutations using saturation mutagenesis, synthetic ligation assembly, ora combination thereof. Alternatively, PCT Publication WO 03/074679 byLazar et al. describes methods of using computational screening methodsto optimize physiochemical properties of antibodies.

Nucleic Acid Molecules Encoding Antibodies of the Invention

Another aspect of the invention pertains to nucleic acid molecules thatencode the antibodies of the invention. The nucleic acids may be presentin whole cells, in a cell lysate, or may be nucleic acids in a partiallypurified or substantially pure form. A nucleic acid is “isolated” or“rendered substantially pure” when purified away from other cellularcomponents or other contaminants, e.g., other cellular nucleic acids orproteins, by standard techniques, including alkaline/SDS treatment, CsClbanding, column chromatography, agarose gel electrophoresis and otherswell known in the art. See, F. Ausubel, et al., ed. 1987 CurrentProtocols in Molecular Biology, Greene Publishing and WileyInterscience, New York. A nucleic acid of the invention can be, forexample, DNA or RNA and may or may not contain intronic sequences. In anembodiment, the nucleic acid is a cDNA molecule. The nucleic acid may bepresent in a vector such as a phage display vector, or in a recombinantplasmid vector.

Nucleic acids of the invention can be obtained using standard molecularbiology techniques. For antibodies expressed by hybridomas (e.g.,hybridomas prepared from transgenic mice carrying human immunoglobulingenes as described further below), cDNAs encoding the light and heavychains of the antibody made by the hybridoma can be obtained by standardPCR amplification or cDNA cloning techniques. For antibodies obtainedfrom an immunoglobulin gene library (e.g., using phage displaytechniques), nucleic acid encoding the antibody can be recovered fromvarious phage clones that are members of the library.

Once DNA fragments encoding V_(H) and V_(L) segments are obtained, theseDNA fragments can be further manipulated by standard recombinant DNAtechniques, for example to convert the variable region genes tofull-length antibody chain genes, to Fab fragment genes or to an scFvgene. In these manipulations, a V_(L)- or V_(H)-encoding DNA fragment isoperatively linked to another DNA molecule, or to a fragment encodinganother protein, such as an antibody constant region or a flexiblelinker. The term “operatively linked”, as used in this context, isintended to mean that the two DNA fragments are joined in a functionalmanner, for example, such that the amino acid sequences encoded by thetwo DNA fragments remain in-frame, or such that the protein is expressedunder control of a desired promoter.

The isolated DNA encoding the V_(H) region can be converted to afull-length heavy chain gene by operatively linking the V_(H)-encodingDNA to another DNA molecule encoding heavy chain constant regions (CH1,CH2 and CH3). The sequences of human heavy chain constant region genesare known in the art (see e.g., Kabat, E. A., et al., 1991 Sequences ofProteins of Immunological Interest, Fifth Edition, U.S. Department ofHealth and Human Services, NIH Publication No. 91-3242) and DNAfragments encompassing these regions can be obtained by standard PCRamplification. The heavy chain constant region can be an IgG1, IgG2,IgG3, IgG4, IgA, IgE, IgM or IgD constant region. For a Fab fragmentheavy chain gene, the V_(H)-encoding DNA can be operatively linked toanother DNA molecule encoding only the heavy chain CH 1 constant region.

The isolated DNA encoding the V_(L) region can be converted to afull-length light chain gene (as well as to a Fab light chain gene) byoperatively linking the V_(L)-encoding DNA to another DNA moleculeencoding the light chain constant region, CL. The sequences of humanlight chain constant region genes are known in the art (see e.g., Kabat,E. A., et al., 1991 Sequences of Proteins of Immunological Interest,Fifth Edition, U.S. Department of Health and Human Services, NIHPublication No. 91-3242) and DNA fragments encompassing these regionscan be obtained by standard PCR amplification. The light chain constantregion can be a kappa or a lambda constant region.

To create an scFv gene, the V_(H)- and V_(L)-encoding DNA fragments areoperatively linked to another fragment encoding a flexible linker, e.g.,encoding the amino acid sequence (Gly4-Ser)₃, such that the V_(H) andV_(L) sequences can be expressed as a contiguous single-chain protein,with the V_(L) and V_(H) regions joined by the flexible linker (seee.g., Bird et al., 1988 Science 242:423-426; Huston et at., 1988 Proc.Natl. Acad. Sci. USA 85:5879-5883; McCafferty et al., 1990 Nature348:552-554).

Production of Monoclonal Antibodies of the Invention

Monoclonal antibodies (mAbs) can be produced by a variety of techniques,including conventional monoclonal antibody methodology e.g., thestandard somatic cell hybridization technique of Kohler and Milstein,1975 Nature 256: 495. Many techniques for producing monoclonal antibodycan be employed e.g., viral or oncogenic transformation of Blymphocytes.

An animal system for preparing hybridomas is the murine system.Hybridoma production in the mouse is a well established procedureImmunization protocols and techniques for isolation of immunizedsplenocytes for fusion are known in the art. Fusion partners (e.g.,murine myeloma cells) and fusion procedures are also known. Monolconalantibodies can also be produced using a specific hybridoma, which hasbeen deposited in a strain collection.

Chimeric or humanized antibodies of the present invention can beprepared based on the sequence of a murine monoclonal antibody preparedas described above. DNA encoding the heavy and light chainimmunoglobulins can be obtained from the murine hybridoma of interestand engineered to contain non-murine (e.g., human) immunoglobulinsequences using standard molecular biology techniques. For example, tocreate a chimeric antibody, the murine variable regions can be linked tohuman constant regions using methods known in the art (see e.g., U.S.Pat. No. 4,816,567 to Cabilly et al.). To create a humanized antibody,the murine CDR regions can be inserted into a human framework usingmethods known in the art (see e.g., U.S. Pat. No. 5,225,539 to Winter,and U.S. Pat. Nos. 5,530,101; 5,585,089; 5,693,762 and 6,180,370 toQueen et al.

In a certain embodiment, the antibodies of the invention are humanmonoclonal antibodies. Such human monoclonal antibodies directed againsthTSLP can be generated using transgenic or transchromosomic micecarrying parts of the human immune system rather than the mouse system.These transgenic and transchromosomic mice include mice referred toherein as HuMAb mice and KM mice, respectively, and are collectivelyreferred to herein as “human Ig mice.”

The HuMAb Mouse® (Medarex, Inc.) contains human immunoglobulin geneminiloci that encode un-rearranged human heavy (μ and γ) and κ lightchain immunoglobulin sequences, together with targeted mutations thatinactivate the endogenous μ and κ chain loci (see e.g., Lonberg, et al.,1994 Nature 368(6474): 856-859). Accordingly, the mice exhibit reducedexpression of mouse IgM or κ, and in response to immunization, theintroduced human heavy and light chain transgenes undergo classswitching and somatic mutation to generate high affinity human IgGκmonoclonal (Lonberg, N. et al., 1994 supra; reviewed in Lonberg, N.,1994 Handbook of Experimental Pharmacology 113:49-101; Lonberg, N. andHuszar, D., 1995 Intern. Rev. Immunol. 13: 65-93, and Harding, F. andLonberg, N., 1995 Ann. N.Y. Acad. Sci. 764:536-546). The preparation anduse of HuMAb mice, and the genomic modifications carried by such mice,is further described in Taylor, L. et al., 1992 Nucleic Acids Research20:6287-6295; Chen, J. et at., 1993 International Immunology 5: 647-656;Tuaillon et al., 1993 Proc. Natl. Acad. Sci. USA 94:3720-3724; Choi etal., 1993 Nature Genetics 4:117-123; Chen, J. et al., 1993 EMBO J. 12:821-830; Tuaillon et al., 1994 J. Immunol. 152:2912-2920; Taylor, L. etal., 1994 International Immunology 579-591; and Fishwild, D. et al.,1996 Nature Biotechnology 14: 845-851, the contents of all of which arehereby specifically incorporated by reference in their entirety. Seefurther, U.S. Pat. Nos. 5,545,806; 5,569,825; 5,625,126; 5,633,425;5,789,650; 5,877,397; 5,661,016; 5,814,318; 5,874,299; and 5,770,429;all to Lonberg and Kay; U.S. Pat. No. 5,545,807 to Surani et al.; PCTPublication Nos. WO 92103918, WO 93/12227, WO 94/25585, WO 97113852, WO98/24884 and WO 99/45962, all to Lonberg and Kay; and PCT PublicationNo. WO 01/14424 to Korman et al.

In another embodiment, human antibodies of the invention can be raisedusing a mouse that carries human immunoglobulin sequences on transgenesand transchomosomes such as a mouse that carries a human heavy chaintransgene and a human light chain transchromosome. Such mice, referredto herein as “KM mice”, are described in detail in PCT Publication WO02/43478 to Ishida et al.

Still further, alternative transgenic animal systems expressing humanimmunoglobulin genes are available in the art and can be used to raiseanti-hTSLP antibodies of the invention. For example, an alternativetransgenic system referred to as the Xenomouse (Abgenix, Inc.) can beused; such mice are described in, for example, U.S. Pat. Nos. 5,939,598;6,075,181; 6,114,598; 6,150,584 and 6,162,963 to Kucherlapati et al.

Moreover, alternative transchromosomic animal systems expressing humanimmunoglobulin genes are available in the art and can be used to raiseanti-hTSLP antibodies of the invention. For example, mice carrying botha human heavy chain transchromosome and a human light chaintranchromosome, referred to as “TC mice” can be used; such mice aredescribed in Tomizuka et al., 2000 Proc. Natl. Acad. Sci. USA97:722-727. Furthermore, cows carrying human heavy and light chaintranschromosomes have been described in the art (Kuroiwa et al., 2002Nature Biotechnology 20:889-894) and can be used to raise anti-hTSLPantibodies of the invention.

Human monoclonal antibodies of the invention can also be prepared usingphage display methods for screening libraries of human immunoglobulingenes. Such phage display methods for isolating human antibodies areestablished in the art. See for example: U.S. Pat. Nos. 5,223,409;5,403,484; and 5,571,698 to Ladner et al.; U.S. Pat. Nos. 5,427,908 and5,580,717 to Dower et al.; U.S. Pat. Nos. 5,969,108 and 6,172,197 toMcCafferty et al.; and U.S. Pat. Nos. 5,885,793; 6,521,404; 6,544,731;6,555,313; 6,582,915 and 6,593,081 to Griffiths et al.

Human monoclonal antibodies of the invention can also be prepared usingSCID mice into which human immune cells have been reconstituted suchthat a human antibody response can be generated upon immunization. Suchmice are described in, for example, U.S. Pat. Nos. 5,476,996 and5,698,767 to Wilson et al.

Antibodies obtained from screening of antibody human libraries, (e.g.phage display with Morphosys), from libraries such as HuCal library fromMorphosys, affinity maturation technology and further codon optimizationsequence technologies can also be used. Affinity maturation can also beused on antibodies made in other ways (e.g., hybridomas).

Generation of Transfectomas Producing Monoclonal Antibodies

Antibodies of the invention also can be produced in a host celltransfectoma using, for example, a combination of recombinant DNAtechniques and gene transfection methods as is well known in the art(e.g., Morrison, S. (1985) Science 229:1202).

For example, to express the antibodies, or antibody fragments thereof,DNAs encoding partial or full-length light and heavy chains, can beobtained by standard molecular biology techniques (e.g., PCRamplification or cDNA cloning using a hybridoma that expresses theantibody of interest) and the DNAs can be inserted into expressionvectors such that the genes are operatively linked to transcriptionaland translational control sequences. In this context, the term“operatively linked” is intended to mean that an antibody gene isligated into a vector such that transcriptional and translationalcontrol sequences within the vector serve their intended function ofregulating the transcription and translation of the antibody gene. Theexpression vector and expression control sequences are chosen to becompatible with the expression host cell used. The antibody light chaingene and the antibody heavy chain gene can be inserted into separatevector or, more typically, both genes are inserted into the sameexpression vector. The antibody genes are inserted into the expressionvector by standard methods (e.g., ligation of complementary restrictionsites on the antibody gene fragment and vector, or blunt end ligation ifno restriction sites are present). The light and heavy chain variableregions of the antibodies described herein can be used to createfull-length antibody genes of any antibody isotype by inserting theminto expression vectors already encoding heavy chain constant and lightchain constant regions of the desired isotype such that the V_(H)segment is operatively linked to the CH segment(s) within the vector andthe V_(L) segment is operatively linked to the CL segment within thevector. Additionally or alternatively, the recombinant expression vectorcan encode a signal peptide that facilitates secretion of the antibodychain from a host cell. The antibody chain gene can be cloned into thevector such that the signal peptide is linked in frame to the aminoterminus of the antibody chain gene. The signal peptide can be animmunoglobulin signal peptide or a heterologous signal peptide (i.e., asignal peptide from a non-immunoglobulin protein).

In addition to the antibody chain genes, the recombinant expressionvectors of the invention carry regulatory sequences that control theexpression of the antibody chain genes in a host cell. The term“regulatory sequence” is intended to include promoters, enhancers andother expression control elements (e.g., polyadenylation signals) thatcontrol the transcription or translation of the antibody chain genes.Such regulatory sequences are described, for example, in Goeddel (GeneExpression Technology. Methods in Enzymology 185, Academic Press, SanDiego, Calif. 1990). It will be appreciated by those skilled in the artthat the design of the expression vector, including the selection ofregulatory sequences, may depend on such factors as the choice of thehost cell to be transformed, the level of expression of protein desired,etc. Regulatory sequences for mammalian host cell expression includeviral elements that direct high levels of protein expression inmammalian cells, such as promoters and/or enhancers derived fromcytomegalovirus (CMV), Simian Virus 40 (SV40), adenovirus (e.g., theadenovirus major late promoter (AdMLP)), and polyoma. Alternatively,nonviral regulatory sequences may be used, such as the ubiquitinpromoter or P-globin promoter. Still further, regulatory elementscomposed of sequences from different sources, such as the SRa promotersystem, which contains sequences from the SV40 early promoter and thelong terminal repeat of human T cell leukemia virus type 1 (Takebe, Y.et al., 1988 Mol. Cell. Biol. 8:466-472).

In addition to the antibody chain genes and regulatory sequences, therecombinant expression vectors of the invention may carry additionalsequences, such as sequences that regulate replication of the vector inhost cells (e.g., origins of replication) and selectable marker genes.The selectable marker gene facilitates selection of host cells intowhich the vector has been introduced (see, e.g., U.S. Pat. Nos.4,399,216, 4,634,665 and 5,179,017, all by Axel et al.). For example,typically the selectable marker gene confers resistance to drugs, suchas G418, hygromycin or methotrexate, on a host cell into which thevector has been introduced. Selectable marker genes include thedihydrofolate reductase (DHFR) gene (for use in dhfr− host cells withmethotrexate selection/amplification) and the neo gene (for G418selection).

For expression of the light and heavy chains, the expression vector(s)encoding the heavy and light chains is transfected into a host cell bystandard techniques. The various forms of the term “transfection” areintended to encompass a wide variety of techniques commonly used for theintroduction of exogenous DNA into a prokaryotic or eukaryotic hostcell, e.g., electroporation, calcium-phosphate precipitation,DEAE-dextran transfection and the like. It is theoretically possible toexpress the antibodies of the invention in either prokaryotic oreukaryotic host cells. Expression of antibodies in eukaryotic cells, inparticular mammalian host cells, is discussed because such eukaryoticcells, and in particular mammalian cells, are more likely thanprokaryotic cells to assemble and secrete a properly folded andimmunologically active antibody. Prokaryotic expression of antibodygenes has been reported to be ineffective for production of high yieldsof active antibody (Boss, M. A. and Wood, C. R., 1985 Immunology Today6:12-13).

Mammalian host cells for expressing the recombinant antibodies of theinvention include Chinese Hamster Ovary (CHO cells) (including dhfr− CHOcells, described Urlaub and Chasin, 1980 Proc. Natl. Acad. Sci. USA77:4216-4220 used with a DH FR selectable marker, e.g., as described inR. J. Kaufman and P. A. Sharp, 1982 Mol. Biol. 159:601-621, NSO myelomacells, COS cells and SP2 cells. When recombinant expression vectorsencoding antibody genes are introduced into mammalian host cells, theantibodies are produced by culturing the host cells for a period of timesufficient to allow for expression of the antibody in the host cells orsecretion of the antibody into the culture medium in which the hostcells are grown. Antibodies can be recovered from the culture mediumusing standard protein purification methods.

Sequences encoding partial or full-length light and heavy chains areexpressed by transfecting the expression vector(s) carrying suchsequences into a host cell by standard transfection techniques.Typically, eukaryotic host cells are used for expressing antibodies, asantibodies are generally glycoproteins and prokaryotic cells aretherefore not appropriate. Mammalian host cells which can be used forexpressing the recombinant antibodies include Chinese Hamster Ovary (CHOcells) (including dhfr− CHO cells), NSO myeloma cells, COS cells and SP2cells. Alternatively, one can use a host cell engineered to produceglycoproteins with mammalian-like glycosylation patterns, includingyeast, fungi or plant cell lines. The antibodies can be produced forexample in glycoengineered yeast cell lines, including Pichia,Saccharomyces or Kluyveromyces species, and preferably, Pichia pastorisor Saccharomyces cerevisae or Kluyveromyces lactis, see for exampleEP1297172B1 (Glycofi). The antibodies can also be produced inglycoengineered plant cell lines, and preferably bryophyte cell lines asdescribed in WO2004057002 (Greenovation). Antibodies are produced byculturing the host cells for a period of time sufficient to allow forexpression of the antibody in the host cells or secretion of theantibody into the culture medium. Antibodies are recovered from theculture medium using standard protein purification methods.

Immunoconjugates

In another aspect, the present invention features an anti-hTSLPantibody, or a fragment thereof, conjugated to a therapeutic moiety,such as a cytotoxin, a drug (e.g., an immunosuppressant) or aradiotoxin. Such conjugates are referred to herein as “immunoconjugates”Immunoconjugates that include one or more cytotoxins are referred to as“immunotoxins.” A cytotoxin or cytotoxic agent includes any agent thatis detrimental to (e.g., kills) cells. Examples include taxon,cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin,etoposide, tenoposide, vincristine, vinblastine, t. colchicin,doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone,mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids,procaine, tetracaine, lidocaine, propranolol, and puromycin and analogsor homologs thereof. Therapeutic agents also include, for example,antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine,cytarabine, 5-fluorouracil decarbazine), ablating agents (e.g.,mechlorethamine, thioepa chloraxnbucil, meiphalan, carmustine (BSNU) andlomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol,streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP)cisplatin, anthracyclines (e.g., daunorubicin (formerly daunomycin) anddoxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin),bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents(e.g., vincristine and vinblastine).

Other examples of therapeutic cytotoxins that can be conjugated to anantibody of the invention include duocarmycins, calicheamicins,maytansines and auristatins, and derivatives thereof. An example of acalicheamicin antibody conjugate is commercially available (Mylotarg™;Wyeth-Ayerst).

Cytotoxins can be conjugated to antibodies of the invention using linkertechnology available in the art. Examples of linker types that have beenused to conjugate a cytotoxin to an antibody include, but are notlimited to, hydrazones, thioethers, esters, disulfides andpeptide-containing linkers. A linker can be chosen that is, for example,susceptible to cleavage by low pH within the lysosomal compartment orsusceptible to cleavage by proteases, such as proteases preferentiallyexpressed in tumor tissue such as cathepsins (e.g., cathepsins B, C, D).

For further discussion of types of cytotoxins, linkers and methods forconjugating therapeutic agents to antibodies, see also Saito, G. et al.,2003 Adv. Drug Deliv. Rev. 55:199-215; Trail, P. A. et al., 2003 CancerImmunol. Immunother. 52:328-337; Payne, G., 2003 Cancer Cell 3:207-212;Allen, T. M., 2002 Nat. Rev. Cancer 2:750-763; Pastan, I. and Kreitman,R. J., 2002 Curr. Opin. Investig. Drugs 3:1089-1091; Senter, P. D. andSpringer, C. J., 2001 Adv. Drug Deliv. Rev. 53:247-264.

Antibodies of the present invention also can be conjugated to aradioactive isotope to generate cytotoxic radiopharmaceuticals, alsoreferred to as radioimmunoconjugates. Examples of radioactive isotopesthat can be conjugated to antibodies for use diagnostically ortherapeutically include, but are not limited to, iodine¹³¹, indium¹¹¹,yttrium⁹⁰, and lutetium¹⁷⁷. Method for preparing radioimmunconjugatesare established in the art. Examples of radioimmunoconjugates arecommercially available, including Zevalin™ (DEC Pharmaceuticals) andBexxar™ (Corixa Pharmaceuticals), and similar methods can be used toprepare radioimmunoconjugates using the antibodies of the invention.

The antibody conjugates of the invention can be used to modify a givenbiological response, and the drug moiety is not to be construed aslimited to classical chemical therapeutic agents. For example, the drugmoiety may be a protein or polypeptide possessing a desired biologicalactivity. Such proteins may include, for example, an enzymaticallyactive toxin, or active fragment thereof, such as abrin, ricin A,pseudomonas exotoxin, or diphtheria toxin; a protein such as tumornecrosis factor or interferon-γ; or, biological response modifiers suchas, for example, lymphokines, interleukin-1 (“IL-1”), interleukin-2(“IL-2”), interleukin-6 (“IL-6”), granulocyte macrophage colonystimulating factor (“GM-CSF”), granulocyte colony stimulating factor(“G-CSF”), or other growth factors.

Techniques for conjugating such therapeutic moiety to antibodies arewell known, see, e.g., Amon et al., “Monoclonal Antibodies ForImmunotargeting Of Drugs In Cancer Therapy”, in Monoclonal AntibodiesAnd Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss,Inc. 1985); Hellstrom et at., “Antibodies For Drug Delivery”, inControlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-53(Marcel Dekker, Inc. 1987); Thorpe, “Antibody Carriers Of CytotoxicAgents In Cancer Therapy: A Review”, in Monoclonal Antibodies '84:Biological And Clinical Applications, Pinchera et al. (eds.), pp.475-506 (1985); “Analysis, Results, And Future Prospective Of TheTherapeutic Use Of Radiolabeled Antibody In Cancer Therapy”, inMonoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al.(eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., “ThePreparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”,Immunol. Rev., 62:119-58 (1982).

Bispecific Molecules

In another aspect, the present invention features bispecific moleculescomprising an anti-hTSLP antibody, or a fragment thereof, of theinvention. An antibody of the invention, or antigen-binding portionsthereof, can be derivatized or linked to another functional molecule,e.g., another peptide or protein (e.g., another antibody or ligand for areceptor) to generate a bispecific molecule that binds to at least twodifferent binding sites or target molecules. The antibody of theinvention may in fact be derivatized or linked to more than one otherfunctional molecule to generate multi-specific molecules that bind tomore than two different binding sites and/or target molecules; suchmulti-specific molecules are also intended to be encompassed by the term“bispecific molecule” as used herein. To create a bispecific molecule ofthe invention, an antibody of the invention can be functionally linked(e.g., by chemical coupling, genetic fusion, noncovalent association orotherwise) to one or more other binding molecules, such as anotherantibody, antibody fragment, peptide or binding mimetic, such that abispecific molecule results.

Accordingly, the present invention includes bispecific moleculescomprising at least one first binding specificity for hTSLP and a secondbinding specificity for a second target epitope. For example, the secondtarget epitope is an Fc receptor, e.g., human FcγRI (CD64) or a humanFcα receptor (CD89). Therefore, the invention includes bispecificmolecules capable of binding both to FcγR, FcαR or FcεR expressingeffector cells (e.g., monocytes, macrophages or polymorphonuclear cells(PMNs), and to target cells expressing hTSLP. These bispecific moleculestarget hTSLP expressing cells to effector cell and trigger Fcreceptor-mediated effector cell activities, such as phagocytosis of anhTSLP expressing cells, antibody dependent cell-mediated cytotoxicity(ADCC), cytokine release, or generation of superoxide anion.

Additionally, for the invention in which the bispecific molecule ismulti-specific, the molecule can further include a third bindingspecificity, in addition to an anti-Fc binding specificity and ananti-hTSLP binding specificity. For example, the third bindingspecificity could be an anti-enhancement factor (EF) portion, e.g., amolecule which binds to a surface protein involved in cytotoxic activityand thereby increases the immune response against the target cell. The“anti-enhancement factor portion” could be an antibody, functionalantibody fragment or a ligand that binds to a given molecule, e.g., anantigen or a receptor, and thereby results in an enhancement of theeffect of the binding determinants for the Fc receptor or target cellantigen.

The “anti-enhancement factor portion” can bind an Fc receptor or atarget cell antigen. Alternatively, the anti-enhancement factor portioncould bind to an entity that is different from the entity to which thefirst and second binding specificities bind. For example, theanti-enhancement factor portion can bind a cytotoxic T-cell (e.g. byCD2, CD3, CD8, CD28, CD4, CD44, ICAM-1 or other immune cell that resultsin an increased immune response against the target cell).

In one embodiment, the bispecific molecules of the invention comprise asa binding specificity at least one antibody, or an antibody fragmentthereof, including, e.g., an Fab, Fab′, F(ab′)₂, Fv, or a single chainFv. The antibody may also be a light chain or heavy chain dimer, or anyminimal fragment thereof such as a Fv or a single chain construct asdescribed in Ladner et al. U.S. Pat. No. 4,946,778, the contents ofwhich is expressly incorporated by reference.

In one embodiment, the binding specificity for an Fcγ receptor isprovided by a monoclonal antibody, the binding of which is not blockedby human immunoglobulin G (IgG). As used herein, the term “IgG receptor”refers to any of the eight γ-chain genes located on chromosome 1. Thesegenes encode a total of twelve transmembrane or soluble receptorisoforms which are grouped into three Fγ receptor classes: FcγRI (CD64),FcγRII (CD32), and FcγRIII (CD 16). In another embodiment, the Fcγreceptor is a human high affinity FcγRI. The human FcγRI is a 72 kDamolecule, which shows high affinity for monomeric IgG (10⁸-10⁹ M⁻¹).

The production and characterization of certain anti-Fcγ monoclonalantibodies are described by Fanger et at. in PCT Publication WO 88/00052and in U.S. Pat. No. 4,954,617, the teachings of which are fullyincorporated by reference herein. These antibodies bind to an epitope ofFcγRI, FcγRII or FcγRIII at a site which is distinct from the Fcγbinding site of the receptor and, thus, their binding is not blockedsubstantially by physiological levels of IgG. Specific anti-FcγRIantibodies useful in this invention are mAb 22, mAb 32, mAb 44, mAb 62and mAb 197. The hybridoma producing mAb 32 is available from theAmerican Type Culture Collection, ATCC Accession No. HB9469. In otherembodiments, the anti-Fcγ receptor antibody is a humanized form ofmonoclonal antibody 22 (H22). The production and characterization of theH22 antibody is described in Graziano, R. F. et al., 1995 J. Immunol 155(10): 4996-5002 and PCT Publication WO 94/10332. The 1122 antibodyproducing cell line was deposited at the American Type CultureCollection under the designation HA022CL1 and has the accession no. CRL11177.

In still other embodiments, the binding specificity for an Fc receptoris provided by an antibody that binds to a human IgA receptor, e.g., anFc-alpha receptor (FcαRI (CD89), the binding of which does not have tobe blocked by human immunoglobulin A (IgA). The term “IgA receptor” isintended to include the gene product of one a gene (FcαRI) located onchromosome 19. This gene is known to encode several alternativelyspliced transmembrane isoforms of 55 to 110 kDa. FcαRI (CD89) isconstitutively expressed on monocytes/macrophages, eosinophilic andneutrophilic granulocytes, but not on non-effector cell populations.FcαRI has medium affinity (5×10⁷ M⁻¹) for both IgA1 and IgA2, which isincreased upon exposure to cytokines such as G-CSF or GM-CSF (Morton, H.C. et al., 1996 Critical Reviews in Immunology 116:423-440). FourFcαRI-specific monoclonal antibodies, identified as A3, A59, A62 andA77, which bind FcαRI outside the IgA ligand binding domain, have beendescribed (Monteiro, R. C. et al., 1992 J. Immunol. 148:1764).

FcαRI and FcγRI are trigger receptors for use in the bispecificmolecules of the invention because they are expressed primarily onimmune effector cells, e.g., monocytes, PMNs, macrophages and dendriticcells; expressed at high levels (e.g., 5,000-100,000 per cell);mediators of cytotoxic activities (e.g., ADCC, phagocytosis); mediateenhanced antigen presentation of antigens, including self-antigens,targeted to them.

Other antibodies which can be employed in the bispecific molecules ofthe invention are murine, chimeric and humanized monoclonal antibodies.

The bispecific molecules of the present invention can be prepared byconjugating the constituent binding specificities, e.g., the anti-FcRand anti-hTSLP binding specificities, using methods known in the art.For example, each binding specificity of the bispecific molecule can begenerated separately and then conjugated to one another. When thebinding specificities are proteins or peptides, a variety of coupling orcross-linking agents can be used for covalent conjugation. Examples ofcross-linking agents include protein A, carbodiimide,N-succinimidyl-5-acetyl-thioacetate (SATA),5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide(oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), andsulfosuccinimidyl 4-(N-maleimidomethyl)cyclohaxane-1-carboxylate(sulfo-SMCC) (see e.g., Karpovsky et al., 1984 J. Exp. Med. 160:1686;Liu, M A et al., 1985 Proc. Natl. Acad. Sci. USA 82:8648). Other methodsinclude those described in Paulus, 1985 Behring Ins. Mitt. No. 78,118-132; Brennan et al., 1985 Science 229:81-83), and Glennie et al.,1987 J. Immunol. 139: 2367-2375). Conjugating agents are SATA andsulfo-SMCC, both available from Pierce Chemical Co. (Rockford, Ill.).

When the binding specificities are antibodies, they can be conjugated bysulfhydryl bonding of the C-terminus hinge regions of the two heavychains. In a particularly embodiment, the hinge region is modified tocontain an odd number of sulfhydryl residues, for example one, prior toconjugation.

Alternatively, both binding specificities can be encoded in the samevector and expressed and assembled in the same host cell. This method isparticularly useful where the bispecific molecule is a mAb×mAb, mAb×Fab,Fab×F(ab′)₂ or ligand×Fab fusion protein. A bispecific molecule of theinvention can be a single chain molecule comprising one single chainantibody and a binding determinant, or a single chain bispecificmolecule comprising two binding determinants. Bispecific molecules maycomprise at least two single chain molecules. Methods for preparingbispecific molecules are described for example in U.S. Pat. No.5,260,203; U.S. Pat. No. 5,455,030; U.S. Pat. No. 4,881,175; U.S. Pat.No. 5,132,405; U.S. Pat. No. 5,091,513; U.S. Pat. No. 5,476,786; U.S.Pat. No. 5,013,653; U.S. Pat. No. 5,258,498; and U.S. Pat. No.5,482,858.

Binding of the bispecific molecules to their specific targets can beconfirmed by, for example, enzyme-linked immunosorbent assay (ELISA),radioimmunoassay (REA), FACS analysis, bioassay (e.g., growthinhibition), or Western Blot assay. Each of these assays generallydetects the presence of protein-antibody complexes of particularinterest by employing a labeled reagent (e.g., an antibody) specific forthe complex of interest. For example, the FcR-antibody complexes can bedetected using e.g., an enzyme-linked antibody or antibody fragmentwhich recognizes and specifically binds to the antibody-FcR complexes.Alternatively, the complexes can be detected using any of a variety ofother immunoassays. For example, the antibody can be radioactively 4labeled and used in a radioimmunoassay (RIA) (see, for example,Weintraub; B., Principles of Radioimmunoassays, Seventh Training Courseon Radioligand Assay Techniques, The Endocrine Society, March, 1986,which is incorporated by reference herein). The radioactive isotope canbe detected by such means as the use of a γ counter or a scintillationcounter or by autoradiography.

Non-Immunoglobulin Scaffolds

A wide variety of antibody/immunoglobulin frameworks or scaffolds can beemployed so long as the resulting polypeptide includes at least onebinding region which is specific for the target protein. Such frameworksor scaffolds include the 5 main idiotypes of human immunoglobulins, orfragments thereof (such as those disclosed elsewhere herein), andinclude immunoglobulins of other animal species, preferably havinghumanized aspects. Single heavy-chain antibodies such as thoseidentified in camelids are of particular interest in this regard. Novelframeworks, scaffolds and fragments continue to be discovered anddeveloped by those skilled in the art.

In one aspect, the invention pertains to generating non-immunoglobulinbased antibodies using non-immunoglobulin scaffolds onto which CDRs ofthe invention can be grafted. Known or future non-immunoglobulinframeworks and scaffolds may be employed, as long as they comprise abinding region specific for the target protein. Such compounds are knownherein as “polypeptides comprising a target-specific binding region”.Known non-immunoglobulin frameworks or scaffolds include, but are notlimited to, Adnectins (fibronectin) (Compound Therapeutics, Inc.,Waltham, Mass.), ankyrin (Molecular Partners AG, Zurich, Switzerland),domain antibodies (Domantis, Ltd (Cambridge, Mass.) and Ablynx nv(Zwijnaarde, Belgium)), lipocalin (Anticalin) (Pieris Proteolab AG,Freising, Germany), small modular immuno-pharmaceuticals (TrubionPharmaceuticals Inc., Seattle, Wash.), maxybodies (Avidia, Inc.(Mountain View, Calif.)), Protein A (Affibody AG, Sweden) and affilin(gamma-crystallin or ubiquitin) (Scil Proteins GmbH, Halle, Germany).

(i) Adnectins—Compound Therapeutics

The adnectin scaffolds are based on fibronectin type III domain (e.g.,the tenth module of the fibronectin type III (10 Fn3 domain). Thefibronectin type III domain has 7 or 8 beta strands which aredistributed between two beta sheets, which themselves pack against eachother to form the core of the protein, and further containing loops(analogous to CDRs) which connect the beta strands to each other and aresolvent exposed. There are at least three such loops at each edge of thebeta sheet sandwich, where the edge is the boundary of the proteinperpendicular to the direction of the beta strands. (U.S. Pat. No.6,818,418).

These fibronectin-based scaffolds are not an immunoglobulin, althoughthe overall fold is closely related to that of the smallest functionalantibody fragment, the variable region of the heavy chain, whichcomprises the entire antigen recognition unit in camel and llama IgG.Because of this structure, the non-immunoglobulin antibody mimicsantigen binding properties that are similar in nature and affinity tothose of antibodies. These scaffolds can be used in a loop randomizationand shuffling strategy in vitro that is similar to the process ofaffinity maturation of antibodies in vivo. These fibronectin-basedmolecules can be used as scaffolds where the loop regions of themolecule can be replaced with CDRs of the invention using standardcloning techniques.

(ii) Ankyrin—Molecular Partners

The technology is based on using proteins with ankyrin derived repeatmodules as scaffolds for bearing variable regions which can be used forbinding to different targets. The ankyrin repeat module is a 33 aminoacid polypeptide consisting of two anti-parallel α-helices and a β-turn.Binding of the variable regions is mostly optimized by using ribosomedisplay.

(iii) Maxybodies/Avimers—Avidia

Avimers are derived from natural A-domain containing protein such asLRP-1. These domains are used by nature for protein-protein interactionsand in human over 250 proteins are structurally based on A-domains.Avimers consist of a number of different “A-domain” monomers (2-10)linked via amino acid linkers. Avimers can be created that can bind tothe target antigen using the methodology described in, for example,20040175756; 20050053973; 20050048512; and 20060008844.

(vi) Protein A—Affibody

Affibody® affinity ligands are small, simple proteins composed of athree-helix bundle based on the scaffold of one of the IgG-bindingdomains of Protein A. Protein A is a surface protein from the bacteriumStaphylococcus aureus. This scaffold domain consists of 58 amino acids,13 of which are randomized to generate Affibody® libraries with a largenumber of ligand variants (See e.g., U.S. Pat. No. 5,831,012). Affibody®molecules mimic antibodies, they have a molecular weight of 6 kDa,compared to the molecular weight of antibodies, which is 150 kDa. Inspite of its small size, the binding site of Affibody® molecules issimilar to that of an antibody.

(v) Anticalins—Pieris

Anticalins® are products developed by the company Pieris ProteoLab AG.They are derived from lipocalins, a widespread group of small and robustproteins that are usually involved in the physiological transport orstorage of chemically sensitive or insoluble compounds. Several naturallipocalins occur in human tissues or body liquids.

The protein architecture is reminiscent of immunoglobulins, withhypervariable loops on top of a rigid framework. However, in contrastwith antibodies or their recombinant fragments, lipocalins are composedof a single polypeptide chain with 160 to 180 amino acid residues, beingjust marginally bigger than a single immunoglobulin domain.

The set of four loops, which makes up the binding pocket, showspronounced structural plasticity and tolerates a variety of side chains.The binding site can thus be reshaped in a proprietary process in orderto recognize prescribed target molecules of different shape with highaffinity and specificity.

One protein of lipocalin family, the bilin-binding protein (BBP) ofPieris Brassicae has been used to develop anticalins by mutagenizing theset of four loops. One example of a patent application describing“anticalins” is PCT WO 199916873.

(vi) Affilin—Scil Proteins

Affilin™ molecules are small non-immunoglobulin proteins which aredesigned for specific affinities towards proteins and small molecules.New Affilin™ molecules can be very quickly selected from two libraries,each of which is based on a different human derived scaffold protein.

Affilin™ molecules do not show any structural homology to immunoglobulinproteins. Scil Proteins employs two Affilin™ scaffolds, one of which isgamma crystalline, a human structural eye lens protein and the other is“ubiquitin” superfamily proteins. Both human scaffolds are very small,show high temperature stability and are almost resistant to pH changesand denaturing agents. This high stability is mainly due to the expandedbeta sheet structure of the proteins. Examples of gamma crystallinederived proteins are described in WO200104144 and examples of“ubiquitin-like” proteins are described in WO2004106368.

Pharmaceutical Compositions

In another aspect, the present invention provides a composition, e.g., apharmaceutical composition, containing one or a combination ofmonoclonal antibodies, or antigen-binding portion(s) thereof, of thepresent invention, formulated together with a pharmaceuticallyacceptable carrier. Such compositions may include one or a combinationof (e.g., two or more different) antibodies, or immunoconjugates orbispecific molecules of the invention. For example, a pharmaceuticalcomposition of the invention can comprise a combination of antibodies(or immunoconjugates or bispecifics) that bind to different epitopes onthe target antigen or that have complementary activities.

Pharmaceutical compositions of the invention also can be administered incombination therapy, i.e., combined with other agents. For example, thecombination therapy can include an anti-hTSLP antibody of the presentinvention combined with at least one other anti-inflammatory agent.Examples of therapeutic agents that can be used in combination therapyare described in greater detail below in the section on uses of theantibodies of the invention.

As used herein, “pharmaceutically acceptable carrier” includes any andall solvents, dispersion media, coatings, antibacterial and antifungalagents, isotonic and absorption delaying agents, and the like that arephysiologically compatible. The carrier should be suitable forintravenous, intramuscular, subcutaneous, parenteral, spinal orepidermal administration (e.g., by injection or infusion). Depending onthe route of administration, the active compound, i.e., antibody,immunoconjuage, or bispecific molecule, may be coated in a material toprotect the compound from the action of acids and other naturalconditions that may inactivate the compound.

The pharmaceutical compounds of the invention may include one or morepharmaceutically acceptable salts. A “pharmaceutically acceptable salt”refers to a salt that retains the desired biological activity of theparent compound and does not impart any undesired toxicological effects(see e.g., Berge, S. M., et al., 1977 J. Pharm. Sci. 66:1-19). Examplesof such salts include acid addition salts and base addition salts. Acidaddition salts include those derived from nontoxic inorganic acids, suchas hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic,phosphorous and the like, as well as from nontoxic organic acids such asaliphatic mono- and di-carboxylic acids, phenyl-substituted alkanoicacids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromaticsulfonic acids and the like. Base addition salts include those derivedfrom alkaline earth metals, such as sodium, potassium, magnesium,calcium and the like, as well as from nontoxic organic amines, such asN,N′-dibenzylethylenediamine, N-methylglucamine, chloroprocaine,choline, diethanolamine, ethylenediamine, procaine and the like.

A pharmaceutical composition of the invention also may include apharmaceutically acceptable anti-oxidant. Examples of pharmaceuticallyacceptable antioxidants include: water soluble antioxidants, such asascorbic acid, cysteine hydrochloride, sodium bisulfate, sodiummetabisulfite, sodium sulfite and the like; oil-soluble antioxidants,such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylatedhydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, andthe like; and metal chelating agents, such as citric acid,ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid,phosphoric acid, and the like.

Examples of suitable aqueous and nonaqueous carriers that may beemployed in the pharmaceutical compositions of the invention includewater, ethanol, polyols (such as glycerol, propylene glycol,polyethylene glycol, and the like), and suitable mixtures thereof,vegetable oils, such as olive oil, and injectable organic esters, suchas ethyl oleate. Proper fluidity can be maintained, for example, by theuse of coating materials, such as lecithin, by the maintenance of therequired particle size in the case of dispersions, and by the use ofsurfactants.

These compositions may also contain adjuvants such as preservatives,wetting agents, emulsifying agents and dispersing agents. Prevention ofpresence of microorganisms may be ensured both by sterilizationprocedures, supra, and by the inclusion of various antibacterial andantifungal agents, for example, paraben, chlorobutanol, phenol sorbicacid, and the like. It may also be desirable to include isotonic agents,such as sugars, sodium chloride, and the like into the compositions. Inaddition, prolonged absorption of the injectable pharmaceutical form maybe brought about by the inclusion of agents which delay absorption suchas, aluminum monostearate and gelatin.

Pharmaceutically acceptable carriers include sterile aqueous solutionsor dispersions and sterile powders for the extemporaneous preparation ofsterile injectable solutions or dispersion. The use of such media andagents for pharmaceutically active substances is known in the art.Except insofar as any conventional media or agent is incompatible withthe active compound, use thereof in the pharmaceutical compositions ofthe invention is contemplated. Supplementary active compounds can alsobe incorporated into the compositions.

Therapeutic compositions typically must be sterile and stable under theconditions of manufacture and storage. The composition can be formulatedas a solution, microemulsion, liposome, or other ordered structuresuitable to high drug concentration. The carrier can be a solvent ordispersion medium containing, for example, water, ethanol, polyol (forexample, glycerol, propylene glycol, and liquid polyethylene glycol, andthe like), and suitable mixtures thereof. The proper fluidity can bemaintained, for example, by the use of a coating such as lecithin, bythe maintenance of the required particle size in the case of dispersionand by the use of surfactants. In many cases, one can include isotonicagents, for example, sugars, polyalcohols such as mannitol, sorbitol, orsodium chloride in the composition. Prolonged absorption of theinjectable compositions can be brought about by including in thecomposition an agent that delays absorption for example, monostearatesalts and gelatin.

Sterile injectable solutions can be prepared by incorporating the activecompound in the required amount in an appropriate solvent with one or acombination of ingredients enumerated above, as required, followed bysterilization microfiltration. Generally, dispersions are prepared byincorporating the active compound into a sterile vehicle that contains abasic dispersion medium and the required other ingredients from thoseenumerated above. In the case of sterile powders for the preparation ofsterile injectable solutions, the methods of preparation are vacuumdrying and freeze-drying (lyophilization) that yield a powder of theactive ingredient plus any additional desired ingredient from apreviously sterile-filtered solution thereof.

The amount of active ingredient which can be combined with a carriermaterial to produce a single dosage form will vary depending upon thesubject being treated, and the particular mode of administration. Theamount of active ingredient which can be combined with a carriermaterial to produce a single dosage form will generally be that amountof the composition which produces a therapeutic effect. Generally, outof one hundred percent, this amount will range from about 0.01 percentto about ninety-nine percent of active ingredient, from about 0.1percent to about 70 percent, or from about 1 percent to about 30 percentof active ingredient in combination with a pharmaceutically acceptablecarrier.

Dosage regimens are adjusted to provide the optimum desired response(e.g., a therapeutic response). For example, a single bolus may beadministered, several divided doses may be administered over time or thedose may be proportionally reduced or increased as indicated by theexigencies of the therapeutic situation. It is especially advantageousto formulate parenteral compositions in dosage unit form for ease ofadministration and uniformity of dosage. Dosage unit form as used hereinrefers to physically discrete units suited as unitary dosages for thesubjects to be treated; each unit contains a predetermined quantity ofactive compound calculated to produce the desired therapeutic effect inassociation with the required pharmaceutical carrier. The specificationfor the dosage unit forms of the invention are dictated by and directlydependent on the unique characteristics of the active compound and theparticular therapeutic effect to be achieved, and the limitationsinherent in the art of compounding such an active compound for thetreatment of sensitivity in individuals.

For administration of the antibody, the dosage ranges from about 0.0001to 100 mg/kg, and more usually 0.01 to 5 mg/kg, of the host body weight.For example dosages can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3mg/kg body weight, 5 mg/kg body weight or 10 mg/kg body weight or withinthe range of 1-10 mg/kg. An exemplary treatment regime entailsadministration once per week, once every two weeks, once every threeweeks, once every four weeks, once a month, once every 3 months or onceevery three to 6 months. Dosage regimens for an anti-hTSLP antibody ofthe invention include 1 mg/kg body weight or 3 mg/kg body weight byintravenous administration, with the antibody being given using one ofthe following dosing schedules: every four weeks for six dosages, thenevery three months; every three weeks; 3 mg/kg body weight once followedby 1 mg/kg body weight every three weeks.

In some methods, two or more monoclonal antibodies with differentbinding specificities are administered simultaneously, in which case thedosage of each antibody administered falls within the ranges indicated.Antibody is usually administered on multiple occasions. Intervalsbetween single dosages can be, for example, weekly, monthly, every threemonths or yearly. Intervals can also be irregular as indicated bymeasuring blood levels of antibody to the target antigen in the patient.In some methods, dosage is adjusted to achieve a plasma antibodyconcentration of about 1-1000 μg/ml and in some methods about 25-300μg/ml.

Alternatively, antibody can be administered as a sustained releaseformulation, in which case less frequent administration is required.Dosage and frequency vary depending on the half-life of the antibody inthe patient. In general, human antibodies show the longest half-life,followed by humanized antibodies, chimeric antibodies, and nonhumanantibodies. The dosage and frequency of administration can varydepending on whether the treatment is prophylactic or therapeutic. Inprophylactic applications, a relatively low dosage is administered atrelatively infrequent intervals over a long period of time. Somepatients continue to receive treatment for the rest of their lives. Intherapeutic applications, a relatively high dosage at relatively shortintervals is sometimes required until progression of the disease isreduced or terminated or until the patient shows partial or completeamelioration of symptoms of disease. Thereafter, the patient can beadministered a prophylactic regime.

Actual dosage levels of the active ingredients in the pharmaceuticalcompositions of the present invention may be varied so as to obtain anamount of the active ingredient which is effective to achieve thedesired therapeutic response for a particular patient, composition, andmode of administration, without being toxic to the patient. The selecteddosage level will depend upon a variety of pharmacokinetic factorsincluding the activity of the particular compositions of the presentinvention employed, or the ester, salt or amide thereof, the route ofadministration, the time of administration, the rate of excretion of theparticular compound being employed, the duration of the treatment, otherdrugs, compounds and/or materials used in combination with theparticular compositions employed, the age, sex, weight, condition,general health and prior medical history of the patient being treated,and like factors well known in the medical arts.

A “therapeutically effective dosage” of an anti-hTSLP antibody of theinvention can results in a decrease in severity of disease symptoms, anincrease in frequency and duration of disease symptom-free periods, or aprevention of impairment or disability due to the disease affliction.

A composition of the present invention can be administered by one ormore routes of administration using one or more of a variety of methodsknown in the art. As will be appreciated by the skilled artisan, theroute and/or mode of administration will vary depending upon the desiredresults. Routes of administration for antibodies of the inventioninclude intravenous, intramuscular, intradermal, intraperitoneal,subcutaneous, spinal or other parenteral routes of administration, forexample by injection or infusion. The phrase “parenteral administration”as used herein means modes of administration other than enteral andtopical administration, usually by injection, and includes, withoutlimitation, intravenous, intramuscular, intraarterial, intrathecal,intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal,transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular,subarachnoid, intraspinal, epidural and intrastemal injection andinfusion.

Alternatively, an antibody of the invention can be administered by anonparenteral route, such as a topical, epidermal or mucosal route ofadministration, for example, intranasally, orally, vaginally, rectally,sublingually or topically.

The active compounds can be prepared with carriers that will protect thecompound against rapid release, such as a controlled releaseformulation, including implants, transdermal patches, andmicroencapsulated delivery systems. Biodegradable, biocompatiblepolymers can be used, such as ethylene vinyl acetate, polyanhydrides,polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Manymethods for the preparation of such formulations are patented orgenerally known to those skilled in the art. See, e.g., Sustained andControlled Release Drug Delivery Systems, J. R. Robinson, ed., MarcelDekker, Inc., New York, 1978.

Therapeutic compositions can be administered with medical devices knownin the art. For example, in one embodiment, a therapeutic composition ofthe invention can be administered with a needleless hypodermic injectiondevice, such as the devices shown in U.S. Pat. No. 5,399,163; 5,383,851;5,312,335; 5,064,413; 4,941,880; 4,790,824 or 4,596,556. Examples ofwell known implants and modules useful in the present invention include:U.S. Pat. No. 4,487,603, which shows an implantable micro-infusion pumpfor dispensing medication at a controlled rate; U.S. Pat. No. 4,486,194,which shows a therapeutic device for administering medicants through theskin; U.S. Pat. No. 4,447,233, which shows a medication infusion pumpfor delivering medication at a precise infusion rate; U.S. Pat. No.4,447,224, which shows a variable flow implantable infusion apparatusfor continuous drug delivery; U.S. Pat. No. 4,439,196, which shows anosmotic drug delivery system having multi-chamber compartments; and U.S.Pat. No. 4,475,196, which shows an osmotic drug delivery system. Thesepatents are incorporated herein by reference. Many other such implants,delivery systems, and modules are known to those skilled in the art.

In certain embodiments, the human monoclonal antibodies of the inventioncan be formulated to ensure proper distribution in vivo. For example,the blood-brain barrier (BBB) excludes many highly hydrophiliccompounds. To ensure that the therapeutic compounds of the inventioncross the BBB (if desired), they can be formulated, for example, inliposomes. For methods of manufacturing liposomes, see, e.g., U.S. Pat.Nos. 4,522,811; 5,374,548; and 5,399,331. The liposomes may comprise oneor more moieties which are selectively transported into specific cellsor organs, thus enhance targeted drug delivery (see, e.g., V. V. Ranade,1989 J. Cline Pharmacol. 29:685). Exemplary targeting moieties includefolate or biotin (see, e.g., U.S. Pat. No. 5,416,016 to Low et al.);mannosides (Umezawa et al., 1988 Biochem. Biophys. Res. Commun.153:1038); antibodies (P. G. Bloeman et al., 1995 FEBS Lett. 357:140; M.Owais et al., 1995 Antimicrob. Agents Chemother. 39:180); surfactantprotein A receptor (Briscoe et al., 1995 Am. J. Physiol. 1233:134); p120(Schreier et al., 1994 J. Biol. Chem. 269:9090); see also K. Keinanen;M. L. Laukkanen, 1994 FEBS Lett. 346:123; J. J. Killion; I. J. Fidler,1994 Immunomethods 4:273.

Uses and Methods of the Invention

The antibodies (and immunoconjugates and bispecific molecules) of thepresent invention have in vitro and in vivo diagnostic and therapeuticutilities. For example, these molecules can be administered to cells inculture, e.g. in vitro or in vivo, or in a subject, e.g., in vivo, totreat, prevent or diagnose a variety of disorders. The term “subject” asused herein in intended to include human and non-human animals.Non-human animals includes all vertebrates, e.g., mammals andnon-mammals, such as non-human primates, sheep, dogs, cats, cows,horses, chickens, amphibians, and reptiles. The methods are particularlysuitable for treating human patients having a disorder associated withaberrant hTSLP expression. When antibodies to hTSLP are administeredtogether with another agent, the two can be administered in either orderor simultaneously.

In one embodiment, the antibodies (and immunoconjugates and bispecificmolecules) of the invention can be used to detect levels of hTSLP, orlevels of cells that contain hTSLP. This can be achieved, for example,by contacting a sample (such as an in vitro sample) and a control samplewith the anti-hTSLP antibody under conditions that allow for theformation of a complex between the antibody and hTSLP. Any complexesformed between the antibody and hTSLP are detected and compared in thesample and the control. For example, standard detection methods, wellknown in the art, such as ELISA and flow cytometic assays, can beperformed using the compositions of the invention.

Accordingly, in one aspect, the invention further provides methods fordetecting the presence of hTSLP (e.g., hTSLP antigen) in a sample, ormeasuring the amount of hTSLP, comprising contacting the sample, and acontrol sample, with an antibody of the invention, or an antigen bindingportion thereof, which specifically binds to hTSLP, under conditionsthat allow for formation of a complex between the antibody or portionthereof and hTSLP. The formation of a complex is then detected, whereina difference in complex formation between the sample compared to thecontrol sample is indicative of the presence of hTSLP in the sample.

Also within the scope of the invention are kits consisting of thecompositions (e.g., antibodies, human antibodies, immunoconjugates andbispecific molecules) of the invention and instructions for use. The kitcan further contain a least one additional reagent, or one or moreadditional antibodies of the invention (e.g., an antibody having acomplementary activity which binds to an epitope on the target antigendistinct from the first antibody). Kits typically include a labelindicating the intended use of the contents of the kit. The term labelincludes any writing, or recorded material supplied on or with the kit,or which otherwise accompanies the kit.

The invention having been fully described, it is further illustrated bythe following examples and claims, which are illustrative and are notmeant to be further limiting. Those skilled in the art will recognize orbe able to ascertain using no more than routine experimentation,numerous equivalents to the specific procedures described herein. Suchequivalents are within the scope of the present invention and claims.The contents of all references, including issued patents and publishedpatent applications, cited throughout this application are herebyincorporated by reference.

The following examples describe monoclonal, in particular humanmonoclonal, anti-human TSLP antibody that specifically binds to humanTSLP and neutralized its biological activity in different cell basedassays, including primary human cell assays. The developed antibodiesshowed extremely high affinity in the low pM range.

EXAMPLES

For the generation of therapeutic antibodies against human TSLP protein,selections with the MorphoSys HuCAL GOLD® phage display library werecarried out. HuCAL GOLD® is a Fab library based on the HuCAL® concept⁶⁻⁸⁹, in which all six CDRs are diversified, and which employs theCysDisplay™ technology for linking Fab fragments to the phage surface¹⁰.

Example 1 Generation of Human TSLP-Specific Antibodies from the HuCALGOLD® Library

Phagemid Rescue, Phage Amplification, and Purification

The HuCAL GOLD® library was amplified in 2×YT medium containing 34 μg/mlchloramphenicol and 1% glucose (2×YT-CG). After infection with VCSM13helper phages at an OD_(600 nm) of 0.5 (30 min at 37° C. withoutshaking; 30 min at 37° C. shaking at 250 rpm), cells were spun down(4120 g; 5 min; 4° C.), resuspended in 2×YT/34 μg/ml chloramphenicol/50μg/ml kanamycin/0.25 mM IPTG and grown overnight at 22° C. Phages werePEG-precipitated twice from the supernatant, resuspended in PBS/20%glycerol and stored at −80° C.

Phage amplification between two panning rounds was conducted as follows:mid-log phase E. coli TG1 cells were infected with eluted phages andplated onto LB-agar supplemented with 1% of glucose and 34 μg/ml ofchloramphenicol (LB-CG plates). After overnight incubation at 30° C.,the TG1 colonies were scraped off the agar plates and used to inoculate2×YT-CG until an OD_(600 nm) of 0.5 was reached and VCSM13 helper phagesadded for infection as described above.

Pannings with HuCAL GOLD®

For the selection of antibodies recognizing human TSLP two differentpanning strategies were applied. In summary, HuCAL GOLD®phage-antibodies were divided into four pools comprising differentcombinations of VH master genes (pool 1: VH1/5 λκ, pool 2: VH3 λκ, pool3: VH2/4/6 λκ, pool 4: VH1-6 λκ). These pools were individuallysubjected to three rounds of solid phase panning on human TSLP directlycoated to Maxisorp plates and in addition three of solution pannings onbiotinylated TSLP.

The first panning variant was solid phase panning against human TSLP:

2 wells on a Maxisorp plate (F96 Nunc-Immunoplate) were coated with 300μl of 5 μg/ml TSLP—each o/n at 4° C. The coated wells were washed 2×with 350 μl PBS and blocked with 350 μl 5% MPBS for 2 h at RT on amicrotiter plate shaker. For each panning about 10¹³ HuCAL GOLD®phage-antibodies were blocked with equal volume of PBST/5% MP for 2 h atroom temperature. The coated wells were washed 2× with 350 μl PBS afterthe blocking. 300 μl of pre-blocked HuCAL GOLD® phage-antibodies wereadded to each coated well and incubated for 2 h at RT on a shaker.Washing was performed by adding five times 350 μl PBS/0.05% Tween,followed by washing another four times with PBS. Elution of phage fromthe plate was performed with 300 μl 20 mM DTT in 10 mM Tris/HCl pH8 perwell for 10 min. The DTT phage eluate was added to 14 ml of E. coli TG1,which were grown to an OD₆₀₀ of 0.6-0.8 at 37° C. in 2YT medium andincubated in 50 ml plastic tubes for 45 min at 37° C. without shakingfor phage infection. After centrifugation for 10 min at 5000 rpm, thebacterial pellets were each resuspended in 500 μl 2×YT medium, plated on2×YT-CG agar plates and incubated overnight at 30° C. Colonies were thenscraped from the plates and phages were rescued and amplified asdescribed above. The second and third rounds of the solid phase panningon directly coated TSLP was performed according to the protocol of thefirst round except for increasing the stringency of the washingprocedure.

The second panning variant was solution panning against biotinylatedhuman TSLP:

For the solution panning, using biotinylated TSLP coupled to DynabeadsM-280 (Dynal), the following protocol was applied: 1.5 ml Eppendorftubes were blocked with 1.5 ml 2× Chemiblocker diluted 1:1 with PBS overnight at 4° C. 200 μl streptavidin coated magnetic Dynabeads M-280(Dynal) were washed 1× with 200 μl PBS and resuspended in 200 μl 1×Chemiblocker (diluted in 1×PBS). Blocking of beads was performed inpre-blocked tubes over night at 4° C. Phages diluted in 500 μl PBS foreach panning condition were mixed with 500 μl 2× Chemiblocker/0.1% Tween1 h at RT (rotator). Pre-adsorption of phages was performed twice: 50 μlof blocked Streptavidin magnetic beads were added to the blocked phagesand incubated for 30 min at RT on a rotator. After separation of beadsvia a magnetic device (Dynal MPC-E) the phage supernatant (−1 ml) wastransferred to a new blocked tube and pre-adsorption was repeated on 50μl blocked beads for 30 min. Then, 200 nM biotinylated hTSLP was addedto blocked phages in a new blocked 1.5 ml tube and incubated for 1 h atRT on a rotator. 100 μl of blocked streptavidin magnetic beads wereadded to each panning phage pool and incubated 10 min at RT on arotator. Phages bound to biotinylated TSLP were immobilized to themagnetic beads and collected with a magnetic particle separator (DynalMPC-E). Beads were then washed 7× in PBS/0.05% Tween using a rotator,followed by washing another three times with PBS. Elution of phage fromthe Dynabeads was performed adding 300 μl 20 mM DTT in 10 mM Tris/HCl pH8 to each tube for 10 min. Dynabeads were removed by the magneticparticle separator and the supernatant was added to 14 ml of an E. coliTG-1 culture grown to OD_(600 nm) of 0.6-0.8. Beads were then washedonce with 200 μl PBS and together with additionally removed phages thePBS was added to the 14 ml E. coli TG-1 culture. For phage infection,the culture was incubated in 50 ml plastic tubes for 45 min at 37° C.without shaking. After centrifugation for 10 min at 5000 rpm, thebacterial pellets were each resuspended in 500 μl 2×YT medium, plated on2×YT-CG agar plates and incubated overnight at 30° C. Colonies were thenscraped from the plates and phages were rescued and amplified asdescribed above.

The second and third rounds of the solution panning on biotinylated TSLPwas performed according to the protocol of the first round except forincreasing the stringency of the washing procedure.

Subcloning and Expression of Soluble Fab Fragments

The Fab-encoding inserts of the selected HuCAL GOLD® phagemids weresub-cloned into the expression vector pMORPH®X9_Fab_FH (FIG. 1) in orderto facilitate rapid and efficient expression of soluble Fabs. For thispurpose, the plasmid DNA of the selected clones was digested with XbaIand EcoRI, thereby excising the Fab-encoding insert (ompA-VLCL andphoA-Fd), and cloned into the XbaI/EcoRI-digested expression vectorpMORPH®X9_Fab_FH. Fabs expressed from this vector carry two C-terminaltags (FLAG™ and 6×His, respectively) for both, detection andpurification.

Microexpression of HuCAL GOLD® Fab Antibodies in E. coli

Chloramphenicol-resistant single colonies obtained after subcloning ofthe selected Fabs into the pMORPH®X9_Fab_FH expression vector were usedto inoculate the wells of a sterile 96-well microtiter plate containing100 μl 2×YT-CG medium per well and grown overnight at 37° C. 5 μl ofeach E. coli TG-1 culture was transferred to a fresh, sterile 96-wellmicrotiter plate pre-filled with 100 μl 2×YT medium supplemented with 34μg/ml chloramphenicol and 0.1% glucose per well. The microtiter plateswere incubated at 30° C. shaking at 400 rpm on a microplate shaker untilthe cultures were slightly turbid (−2-4 hrs) with an OD_(600 nm) of˜0.5.

To these expression plates, 20 μl 2×YT medium supplemented with 34 μg/mlchloramphenicol and 3 mM IPTG (isopropyl-β-D-thiogalactopyranoside) wasadded per well (end concentration 0.5 mM IPTG), the microtiter platessealed with a gas-permeable tape, and incubated overnight at 30° C.shaking at 400 rpm.

Generation of whole cell lysates (BEL extracts): To each well of theexpression plates, 40 μl BEL buffer (2×BBS/EDTA: 24.7 g/l boric acid,18.7 g NaCl/l, 1.49 g EDTA/l, pH 8.0) was added containing 2.5 mg/mllysozyme and incubated for 1 h at 22° C. on a microtiter plate shaker(400 rpm). The BEL extracts were used for binding analysis by ELISA or aBioVeris M-series® 384 analyzer (see Example 2).

Enzyme Linked Immunosorbent Assay (ELISA) Techniques

5 μg/ml of human recombinant TSLP (R&D Systems) in PBS was coated onto384 well Maxisorp plates (Nunc-Immunoplate) o/n at 4° C. After coatingthe wells were washed once with PBS/0.05% Tween (PBS-T) and 2× with PBS.Then the wells were blocked with PBS-T with 2% BSA for 2 h at RT. Inparallel 15 μl BEL extract and 15 μl PBS-T with 2% BSA were incubatedfor 2 h at RT. The blocked Maxisorp plated were washed 3× with PBS-Tbefore 10 μl of the blocked BEL extracts were added to the wells andincubated for 1 h at RT. For detection of the primary Fab antibodies,the following secondary antibodies were applied: alkaline phospatase(AP)-conjugated AffiniPure F(ab′)₂ fragment, goat anti-human,-anti-mouse or -anti-sheep IgG (Jackson Immuno Research). For thedetection of AP-conjugates fluorogenic substrates like AttoPhos (Roche)were used according to the instructions by the manufacturer. Between allincubation steps, the wells of the microtiter plate were washed withPBS-T three times and three times after the final incubation withsecondary antibody. Fluorescence was measured in a TECAN Spectrafluorplate reader.

Expression of HuCAL GOLD® Fab Antibodies in E. coli and Purification

Expression of Fab fragments encoded by pMORPH®X9_Fab_FH in TG-1 cellswas carried out in shaker flask cultures using 750 ml of 2×YT mediumsupplemented with 34 μg/ml chloramphenicol. Cultures were shaken at 30°C. until the OD_(600 nm) reached 0.5. Expression was induced by additionof 0.75 mM IPTG for 20 h at 30° C. Cells were disrupted using lysozymeand Fab fragments isolated by Ni-NTA chromatography (Qiagen, Hilden,Germany). Protein concentrations were determined byUV-spectrophotometry¹¹.

Example 2 Identification of Neutralizing Anti-Human TSLP Fab Candidatesthat Inhibit TSLP Induced Signaling of the TSLP Receptor

22 different human TSLP specific antibodies, which were selected fromthe HuCAL GOLD® library, were tested for the potency to neutralize humanTSLP.

A. Blocking of TSLP Binding to the TSLP Receptor by Anti-Human TSLP Fabsin FACS Assay

Binding inhibition of biotinylated TSLP to Ba/F3 cells, expressinghTSLPR, hIL7Rα was analyzed by FACS. The Fab antibodies were diluted inFACS buffer (cellwash (B&D)/3% FCS). 50 μl biotinylated TSLP at 100ng/ml was incubated with 50 μl of 100 ng/ml Fab for 1 h at RT. To avoidinternalization of the TSLP receptor all further steps with cells werecarried out at 4° C. or on ice. 100 μl Ba/F3 cells at 2×10⁶ cells/mlwere transferred to each well of a 96 well plate (NUNC) and centrifugedat 2000 rpm; 4° C. Cells were washed 2× with 150 μl cold FACS buffer,resuspended with the Fab/biotinylated TSLP mix and incubated for 1 h at4° C. on a shaker. Streptavidin PE 1:400 in FACS-buffer was added fordetection. After 30 min incubation, cells were centrifuged as mentionedabove and washed 2× with 150 μl cold FACS buffer. 5000 cells wereanalyzed in FACS. MOR04494, MOR04496, MOR04497 and MOR04609 showedinhibition of cell binding.

Inhibition of TSLP Dependent STATS Activation

Ba/F3 cells, expressing hTSLPR, hIL7Rα and a Stat5-Luc reporter gene,were grown in the presence of 5 ng/ml TSLP. 10 μl of 1×10⁶ cells/ml inassay buffer (RPMI-1640 w/o phenol red, 10% FCS, penicillin 10Uml⁻¹/streptomycin 10 μgml⁻¹, 1% puromycin) were added to Costar 96-wellwhite plate (Corning). 70 μl of assay buffer and 10 μl of anti-TSLPantibody (10×) in assay buffer was added and incubated for 20 min at 37°C. 10 μl of 5 ng/ml TSLP (R&D Systems; 0.5 ng/ml final concentration) inassay buffer was added to give a final assay volume of 100 μl. The platewas covered and left for 5-6 h at 37° C. in a humidified incubator. Tothe wells 100 μl (1:1 with assay volume) of Bright-Glo™ luciferase(Promega) were added and incubated for 5 min at RT. The plate was sealedwith TopSeal™ before recording luminescence. MOR04493, MOR04494,MOR04496, MOR04497 and MOR04609 neutralized TSLP in this assay.

Determination of Neutralizing Activity in Primary Monocyte

Isolation of Human Blood Monocytes

150 mL of blood was collected from healthy adult volunteers on the NHRCdonor panel. Blood was collected with tubes containing 1 mL ofanti-coagulant (20 mg/mL EDTA in PBS) per 10 mL blood and then dilutedwith 12.5 mL PBS per 20 mL blood. Red blood cells were then sedimentedby mixing the diluted blood with 12.5 mL 4% Dextran (in PBS) per tubeand incubating for 40 minutes on ice. PBMCs were isolated by densitycentrifugation using Ficoll and the ‘buffy coat’ containing PBMCs wasrecovered using a plastic pastete. The cells were washed once (300×g for7 minutes) in PBS and counted. MACS isolation of cells was carried outaccording to the manufacturers instructions using the Monocyte Isolationkit II (Miltenyi Biotec). All buffer additions and washes were with MACSbuffer at 4° C. (PBS, 0.5% BSA, 2 mM EDTA, pH 7.2) unless otherwisestated. Briefly, to 10⁷ cells, 30 μL of buffer and 10 μL each of FcRBlocking Reagent and Biotin-Antibody Cocktail were added, mixed well andincubated for 10 minutes. A further 30 μL of buffer and 20 μL ofAnti-Biotin Microbeads were then added to the cells and incubated for 15minutes. Cells were washed (300×g for 10 minutes), resuspended at 10⁸cells per 500 μL buffer and applied to the ‘primed’ LS column. The‘untouched’ monocyte fraction was collected by retaining all other celltypes on the column. During the isolation procedure samples werecollected for later analysis by flow cytometry.

TARC Production by Monocytes Treated with TSLP and Blocking the Responsewith Anti-TSLP Antibodies

Freshly isolated monocytes were resuspended at 1×10⁶ cells per mL ofassay buffer (RPMI 1640, 10% FCS, penicillin 10 U/mL/streptomycin 10ng/mL). 100 μL of cells were added to each well of a 96-wellflat-bottomed plate to give a concentration of 100,000 cells per well.80 μL of assay buffer was added to wells that were used for the TSLPdose response curve and 60 μL was added to wells in which anti-TSLPantibodies were to be tested. For the anti-TSLP antibody testing, 20 μLof a 10× stock solution of each anti-TSLP antibody was added to thecells and incubated at 37° C., 5% CO₂ for 20 minutes. rhTSLP was thenadded at 0.5 ng/mL to each well (20 μL of 10× stock solution per well)containing anti-TSLP antibody. A TSLP dose response curve was includedon each plate. Plates were incubated for 24 hours at 37° C., 5% CO₂after which supernatants were harvested and stored at −20° C. for futureanalysis.

ELISA of Monocyte Supernatants to Measure TARC

Measurements of TARC production in culture supernatants was carried outusing a human TARC duoset ELISA kit (R+D Systems) according tomanufacturer's instructions. Briefly monocyte supernatants were diluted1:2 in assay buffer (RPMI 1640, 10% FCS, penicillin 10 U/mL/streptomycin10 μg/mL) and added in triplicate to 96-well half-area plates previouslycoated with TARC capture antibody. Plates were incubated for 2 hours atRT then washed again. 50 μL of biotinylated detection mAb was then addedto each well and incubated for a further 2 hours at RT. Plates werewashed and horseradish peroxidase was added at 50 μL per well andincubated for 20 minutes at RT in the dark. A final wash was carried outand 100 μL of TMB substrate was added per well and plates were incubatedat RT in the dark. Colour development was stopped after 20 minutesincubation by addition of 50 μL 1M sodium hydroxide. Plates were readimmediately on a Spectramax microplate reader set at 450 nm (MolecularDevices). Data was analysed using SoftmaxPro software and percentageinhibition of maximal absorbance response by anti-TSLP antibodies wascalculated using an Excel spreadsheet.

Neutralization of Natural Human TSLP in Receptor Gene Assay

Human natural TSLP was generated by treating primary human fibroblastcells (Clonetics), with a cytokine cocktail containing IL-113 (1 ng/ml),TNF-α (1 ng/ml) and IL-13 (10 ng/ml) for 24 hours at 37° C. inphenol-red free RPMI containing 10% FBS. The cell culture supernatantcontaining induced natural TSLP was shown to be active in the RGAdescribed above.

A 1 in 10 dilution of the natural TSLP containing TSLP corresponded toapproximately the same level of activity in the RGA as 0.5 ng/ml ofrhTSLP and hence was used as the final dilution when testing theactivity of candidate antibodies.

TSLP/TSLP Receptor Binding Inhibition BioVeris Assay

For the TSLP binding inhibition assay, recombinant human TSLP (R&DSystems) was directly coupled (NHS/EDC coupling) to carboxylic acidM-270 Dynal magnetic beads. 50 μl Fab antibodies per well (10 μM stock,1:5 dilution steps) were incubated for 2 h with 25 μl TSLP coated beadsin 96 well plates (Nunc). 50 μl of 100 pM TSLP-receptor/Fc fusion and1:1000 diluted anti-human Fc detection antibody labeled with BV-tag™according to instructions of supplier (BioVeris, Europe, Witney,Oxforfshire, UK) were added to each well and incubated for 1 h. (FinalFab concentration: 32 nM-4 μM, final TSLP conc: 40 μM). Detection wasperformed by BioVeris M-384 SERIES® Workstation (BioVeris Europe,Witney, Oxforfshire, UK). MOR04493, MOR04494, MOR04496, MOR04497,MOR04609, and MOR04832 showed inhibition of TSLP receptor binding inthis assay.

Determination of Nanomolar Affinities Using Surface Plasmon Resonance(Biacore)

Kinetic SPR analysis was performed on a SA-chip (Biacore, Sweden) whichhad been coated with a density of ˜400 RU biotinylated recombinant humanTSLP i. A respective amount of biotinylated human serum albumin (HSA)was immobilized on the reference flow cell. PBS (136 mM NaCl, 2.7 mMKCl, 10 mM Na2HPO4, 1.76 mM KH2PO4 pH 7.4) was used as the runningbuffer. The Fabs were applied in concentration series of 16-500 nM at aflow rate of 20 μl/min. Association phase was set to 60 s anddissociation phase to 120 s. The summarized affinities of the parentalFab antibodies 4493, 4494, 4496, 4497, 4832 and 4609 to human TSLPdetermined by that method are in the range of 8-1400 nM.

Example 3 Affinity Maturation of Selected Anti-TSLP Fabs by ParallelExchange of LCDR3 and HCDR2 Cassettes

B. Generation of Fab Libraries for Affinity Maturation

In order to increase the affinity and inhibitory activity of theidentified anti-TSLP antibodies, 6 Fab clones MOR04493, MOR04494,MOR04496, MOR04497, MOR04609, and MOR04832 were subjected to affinitymaturation. For this purpose, CDR regions were optimized by cassettemutagenesis using trinucleotide directed mutagenesis^(12,13).

The following paragraph briefly describes the protocol used for cloningof the maturation libraries and Fab optimization. Fab fragments fromexpression vector pMORPH®X9_Fab_FH were cloned into the phagemid vectorpMORPH®25 (U.S. Pat. No. 6,753,136). Two different strategies wereapplied in parallel to optimize both, the affinity and the efficacy ofthe parental Fabs.

Six phage antibody Fab libraries were generated where the LCDR3 of sixparental clones was replaced by a repertoire of individual light chainCDR3 sequences. In parallel, the HCDR2 region of each parental clone wasreplaced by a repertoire of individual heavy chain CDR2 sequences.Affinity maturation libraries were generated by standard cloningprocedures and transformation of the diversified clones intoelectro-competent E. coli TOP 10F′ cells (Invitrogen). Fab-presentingphages were prepared as described in Example 1A. Four maturation poolswere built and kept separate during the subsequent selection process:

-   -   pool 1: LCDR3 libraries of MOR04493 and MOR04832    -   pool 2: HCDR2 libraries of MOR04493 and MOR04832    -   pool 3: LCDR3 libraries of MOR04494; MOR04496; MOR04497;        MOR04609    -   pool 4: HCDR2 libraries of MOR04494; MOR04496; MOR04497;        MOR04609

Maturation Panning Strategies

Pannings using the four antibody pools were performed on biotinylatedrecombinant human TSLP (R&D Systems) in solution for three rounds,respectively as described in Example 1B, solution panning againstbiotinylated human TSLP. The selection stringency was increased byreduction of biotinylated antigen from panning round to panning round,by prolonged washing steps and by addition of non-biotinylated antigenfor off-rate selection.

Electrochemiluminescene (BioVeris) Based Binding Analysis for Detectionof TSLP Binding Fab in Bacterial Lysates

Binding of optimized Fab antibodies in E. coli lysates (BEL extracts) toTSLP was analyzed in BioVeris M-SERIES® 384 AnalyzerBioVeris, Europe,Witney, Oxforfshire, UK). BEL extracts were diluted in assay buffer(PBS/0.05% Tween20/0.5% BSA) for use in BioVeris screening. BiotinylatedTSLP (R&D Systems) was coupled to streptavidin coated paramagneticbeads, Anti-human (Fab)′₂ (Dianova) was ruthenium labeled using theBV-tag™ (BioVeris Europe, Witney, Oxfordshire, UK). This secondaryantibody was added to the TSLP coupled beads before measuring in theBioVeris M-SERIES® 384 Analyzer. After sequence analysis of hits fromthe BioVeris screening, 20 unique Fab clones were identified: MOR05008;MOR05009; MOR05010; MOR05011; MOR05012; MOR05013; MOR05014; MOR05015;MOR05016; MOR05017; MOR05018; MOR05019; MOR05020; MOR05021; MOR05022;MOR05023; MOR05024; MOR05025; MOR05026; MOR05027.

IgG Conversion and Cross-Transfection of Two Independently OptimizedVariable Chains in Order to Further Improve the Affinities of theAntibodies

All 20 optimized Fab antibodies were sub-cloned into IgG1 format.Affinity of all 20 IgG1 of MOR05008; MOR05009; MOR05010; MOR05011;MOR05012; MOR05013; MOR05014; MOR05015; MOR05016; MOR05017; MOR05018;MOR05019; MOR05020; MOR05021; MOR05022; MOR05023; MOR05024; MOR05025;MOR05026; MOR05027 was measured in solution equilibrium titration fromtissue culture supernatant.

For a further improvement of affinity the independently optimized H-CDR2and L-CDR3 from matured IgG1s, which were derived from the same parentalclone, were combined, because there was a high probability that thiscombination would lead to a further gain of affinity¹⁴⁻¹⁶. The heavy andthe light chain of the IgG1 were on separate vectors and therefore bycross-transfection it was possible to combine the two differentoptimized chains which were then co-expressed in one cell and assembleto IgG antibodies. This method was applied for binders that were derivedfrom the parental clone MOR04494 and MOR04497, where from both theH-CDR2 and the L-CDR3 library optimized chains were identified inparallel. For MOR04494 all six optimized heavy chains fromMOR05010-MOR05015 were combined one by one with the three optimizedlight chains of MOR05016-MOR05018 resulting in 18 new antibodies. ForMOR04497 the one optimized H-CDR2 of MOR5019 was combined with the threeoptimized light chains of MOR05020-MOR05022 resulting in 3 newantibodies.

Determination of Picomolar Affinities Using Solution EquilibriumTitration (SET)

For K_(D) determination, monomer fractions (at least 90% monomercontent, analyzed by analytical SEC; Superdex75, Amersham Pharmacia) ofFab were used. In addition it was possible to determine the affinitiesof IgG1, as the antigen TSLP is supposed to be a monomer in solution.Electrochemiluminescence (ECL) based affinity determination in solutionand data evaluation were basically performed as described by Haenel etal., 2005. A constant amount of Fab or IgG1 was equilibrated withdifferent concentrations (serial 3^(n) dilutions) of recombinant humanTSLP (R&D Systems) in solution. Biotinylated human TSLP coupled toparamagnetic beads (M-280 Streptavidin, Dynal), and BV-tag™ (BioVerisEurope, Witney, Oxfordshire, UK) labeled anti-human (Fab)′₂ (Dianova)was added and the mixture incubated for 30 min. Subsequently, theconcentration of unbound Fab was quantified via ECL detection using theM-SERIES® 384 analyzer (BioVeris Europe).

Affinity determination to cynomolgus TSLP (mammalian expression andpurification at NVS) in solution was done essentially as described abovereplacing the human TSLP by the cynomolgus TSLP. For detection of freeFab, biotinylated human TSLP coupled to paramagnetic beads was used.Affinities were calculated according to Haenel et al. (2005)¹⁷. Usingthe assay conditions described above (monomeric) affinities for theaffinity-optimized anti-TSLP IgGs were determined in solution. Theaffinities to human and cynomolgus TSLP are summarized in Table 5.

TABLE 5 Affinities of optimized IgG1.

Thus, as a further aspect of the present invention, there is presentedthe use of an isolated hTSLP-binding region of an antibody or functionalfragment thereof having an KD of less than 100 pM, suitably less than 50pM, preferably less than 30 pM, in the treatment of a disease associatedwith the presence of cell receptor target hTSLP, such as asthma oratopic dermatitis.

REFERENCE LIST

-   1. Reche, P. A. et al. Human thymic stromal lymphopoietin    preferentially stimulates myeloid cells. J Immunol 167, 336-343    (2001).-   2. Soumelis, V. et al. Human epithelial cells trigger dendritic cell    mediated allergic inflammation by producing TSLP. Nat Immunol 3,    673-680 (2002).-   3. Levin, S. D. et al. Thymic stromal lymphopoietin: a cytokine that    promotes the development of IgM+B cells in vitro and signals via a    novel mechanism. J Immunol 162, 677-683 (1999).-   4. Novak, N. & Bieber, T. The role of dendritic cell subtypes in the    pathophysiology of atopic dermatitis. J Am Acad. Dermatol. 53,    S171-S176 (2005).-   5. Quentmeier, H. et al. Cloning of human thymic stromal    lymphopoietin (TSLP) and signaling mechanisms leading to    proliferation. Leukemia 15, 1286-1292 (2001).-   6. Knappik, A. et al. Fully synthetic human combinatorial antibody    libraries (HuCAL) based on modular consensus frameworks and CDRs    randomized with trinucleotides. J Mol Biol 296, 57-86 (2000).-   7. Krebs, B. et al. High-throughput generation and engineering of    recombinant human antibodies. J Immunol Methods 254, 67-84 (2001).-   8. Rauchenberger, R. et al. Human combinatorial Fab library yielding    specific and functional antibodies against the human fibroblast    growth factor receptor 3. J Biol Chem 278, 38194-38205 (2003).-   9. Knappik, A. et al. Fully synthetic human combinatorial antibody    libraries (HuCAL) based on modular consensus frameworks and CDRs    randomized with trinucleotides. J Mol Biol 296, 57-86 (2000).-   10. Löhning, C. Novel methods for displaying (poly)peptides/proteins    on bacteriophage particles via disulfide bonds. (WO 01/05950). 2001.    -   Ref Type Patent-   11. Krebs, B. et al. High-throughput generation and engineering of    recombinant human antibodies. J Immunol Methods 254, 67-84 (2001).-   12. Nagy, Z. A. et al. Fully human, HLA-DR-specific monoclonal    antibodies efficiently induce programmed death of malignant lymphoid    cells. Nat Med 8, 801-807 (2002).-   13. Virnekas, B. et al. Trinucleotide phosphoramidites: ideal    reagents for the synthesis of mixed oligonucleotides for random    mutagenesis. Nucleic Acids Res 22, 5600-5607 (1994).-   14. Chen, Y. et al. Selection and analysis of an optimized anti-VEGF    antibody: crystal structure of an affinity-matured Fab in complex    with antigen. J Mol Biol 293, 865-881 (1999).-   15. Schier, R. et al. Isolation of picomolar affinity anti-c-erbB-2    single-chain Fv by molecular evolution of the complementarity    determining regions in the center of the antibody binding site. J    Mol Biol 263, 551-567 (1996).-   16. Yang, W. P. et al. CDR walking mutagenesis for the affinity    maturation of a potent human anti-HIV-1 antibody into the picomolar    range. J Mol Biol 254, 392-403 (1995).-   17. Haenel, C., Satzger, M., Ducata, D. D., Ostendorp, R. &    Brocks, B. Characterization of high-affinity antibodies by    electrochemiluminescence-based equilibrium titration. Anal Biochem    339, 182-184 (2005).

Annex 1 CDR Sequences Of Antibodies Of The InventionVH CDR (H-CDR) Sequences SEQ ID SEQ ID SEQ ID Id no. HCDR 1 # HCDR 2 #HCDR 3 # VH1A G G T F S S — — Y A I S 1 G I I P — — I F G T A N Y A Q KF Q G  8 MOR04493 G G T F S S — — Y A I S 1 G I I P — — D F G W A N Y AQ K F Q G  9 S G M F Y S I L F D Y — — — — 26 MOR05008 G G T F S S — — YA I S 1 G I I P — — E F G F T N Y A Q K F Q G 10 S G M F Y S I L F D Y —— — — 26 MOR05009 G G T F S S — — Y A I S 1 H I S P — — E F G F T N Y AQ K F Q G 11 S G M F Y S I L F D Y — — — — 26 MOR04832 G G T F S S — — YA I S 1 N I Y P — — I F G Y A N Y A Q K F Q G 12 Y G Q Y G Q H F S H G GM D V 27 MOR05023 G G T F S S — — Y A I S 1 N I Y P — — I F G Y A N Y AQ K F Q G 12 Y G Q Y G Q H F S H G G M D V 27 MOR05024 G G T F S S — — YA I S 1 N I Y P — — I F G Y A N Y A Q K F Q G 12 Y G Q Y G Q H F S H G GM D V 27 MOR05025 G G T F S S — — Y A I S 1 N I Y P — — I F G Y A N Y AQ K F Q G 12 Y G Q Y G Q H F S H G G M D V 27 MOR05026 G G T F S S — — YA I S 1 N I Y P — — I F G Y A N Y A Q K F Q G 12 Y G Q Y G Q H F S H G GM D V 27 MOR05027 G G T F S S — — Y A I S 1 N I Y P — — I F G Y A N Y AQ K F Q G 12 Y G Q Y G Q H F S H G G M D V 27 SEQ ID VH3 G F T F S S — —Y A M S 2 A I S G — — S G G S T Y Y A D S V K G 13 NO MOR04494 G F T F SS — — Y Y M S 3 N I S Y — — D S S D T Y Y A D S V K G 14 Q Q Y F D H I DI — — — — — — 28 MOR05010 G F T F S S — — Y Y M S 3 G I F F — — — D G ET Y Y A G S V K G 15 Q Q Y F D H I D I — — — — — — 28 MOR05011 G F T F SS — — Y Y M S 3 G I F Y — — — D G S T Y Y P D S V K G 16 Q Q Y F D H I DI — — — — — — 28 MOR05012 G F T F S S — — Y Y M S 3 G I F F — — — T G ET Y Y P D S V K G 17 Q Q Y F D H I D I — — — — — — 28 MOR05013 G F T F SS — — Y Y M S 3 G I F F — — — D G E T Y Y A D S V K G 18 Q Q Y F D H I DI — — — — — — 28 MOR05014 G F T F S S — — Y Y M S 3 G I F F — — — D G TT Y Y A D S V K G 19 Q Q Y F D H I D I — — — — — — 28 MOR05015 G F T F SS — — Y Y M S 3 G T F F — — — D G S T Y Y A D S V K G 20 Q Q Y F D H I DI — — — — — — 28 MOR05016 G F T F S S — — Y Y M S 3 N I S Y — — D S S DT Y Y A D S V K G 14 Q Q Y F D H I D I — — — — — — 28 MOR05017 G F T F SS — — Y Y M S 3 N I S Y — — D S S D T Y Y A D S V K G 14 Q Q Y F D H I DI — — — — — — 28 MOR05018 G F T F S S — — Y Y M S 3 N I S Y — — D S S DT Y Y A D S V K G 14 Q Q Y F D H I D I — — — — — — 28 MOR05154 G F T F SS — — Y Y M S 3 G I F F — — — D G E T Y Y A G S V K G 15 Q Q Y F D H I DI — — — — — — 28 MOR05155 G F T F S S — — Y Y M S 3 G I F F — — — D G ET Y Y A G S V K G 15 Q Q Y F D H I D I — — — — — — 28 MOR05156 G F T F SS — — Y Y M S 3 G I F F — — — D G E T Y Y A G S V K G 15 Q Q Y F D H I DI — — — — — — 28 MOR05157 G F T F S S — — Y Y M S 3 G I F Y — — — D G ST Y Y P D S V K G 16 Q Q Y F D H I D I — — — — — — 28 MOR05158 G F T F SS — — Y Y M S 3 G I F Y — — — D G S T Y Y P D S V K G 16 Q Q Y F D H I DI — — — — — — 28 MOR05159 G F T F S S — — Y Y M S 3 G I F Y — — — D G ST Y Y P D S V K G 16 Q Q Y F D H I D I — — — — — — 28 MOR05160 G F T F SS — — Y Y M S 3 G I F F — — — T G E T Y Y P D S V K G 17 Q Q Y F D H I DI — — — — — — 28 MOR05161 G F T F S S — — Y Y M S 3 G I F F — — — T G ET Y Y P D S V K G 17 Q Q Y F D H I D I — — — — — — 28 MOR05162 G F T F SS — — Y Y M S 3 G I F F — — — T G E T Y Y P D S V K G 17 Q Q Y F D H I DI — — — — — — 28 MOR05163 G F T F S S — — Y Y M S 3 G I F F — — — D G ET Y Y A D S V K G 18 Q Q Y F D H I D I — — — — — — 28 MOR05164 G F T F SS — — Y Y M S 3 G I F F — — — D G E T Y Y A D S V K G 18 Q Q Y F D H I DI — — — — — — 28 MOR05165 G F T F S S — — Y Y M S 3 G I F F — — — D G ET Y Y A D S V K G 18 Q Q Y F D H I D I — — — — — — 28 MOR05166 G F T F SS — — Y Y M S 3 G I F F — — — D G T T Y Y A D S V K G 19 Q Q Y F D H I DI — — — — — — 28 MOR05167 G F T F S S — — Y Y M S 3 G I F F — — — D G TT Y Y A D S V K G 19 Q Q Y F D H I D I — — — — — — 28 MOR05168 G F T F SS — — Y Y M S 3 G I F F — — — D G T T Y Y A D S V K G 19 Q Q Y F D H I DI — — — — — — 28 MOR05169 G F T F S S — — Y Y M S 3 G T F F — — — D G ST Y Y A D S V K G 20 Q Q Y F D H I D I — — — — — — 28 MOR05170 G F T F SS — — Y Y M S 3 G T F F — — — D G S T Y Y A D S V K G 20 Q Q Y F D H I DI — — — — — — 28 MOR05171 G F T F S S — — Y Y M S 3 G T F F — — — D G ST Y Y A D S V K G 20 Q Q Y F D H I D I — — — — — — 28 MOR04496 G F T F SS — — Y A I S 4 S I S Y — — S G S S T Y Y A D S V K G 21 M E Y W Y H L LY M D Y — — — 29 MOR04497 G F T F S N — — H A L S 5 G I Q Y — — D G S NT G Y A D S V K G 22 Y Y G Y S Y M D Y — — — — — — 30 MOR05019 G F T F SN — — H A L S 5 V I S F — — — D G V K F Y A D S V K G 23 Y Y G Y S Y M DY — — — — — — 30 MOR05020 G F T F S N — — H A L S 5 G I Q Y — — D G S NT G Y A D S V K G 22 Y Y G Y S Y M D Y — — — — — — 30 MOR05021 G F T F SN — — H A L S 5 G I Q Y — — D G S N T G Y A D S V K G 22 Y Y G Y S Y M DY — — — — — — 30 MOR05022 G F T F S N — — H A L S 5 G I Q Y — — D G S NT G Y A D S V K G 22 Y Y G Y S Y M D Y — — — — — — 30 MOR05172 G F T F SN — — H A L S 5 V I S F — — — D G V K F Y A D S V K G 23 Y Y G Y S Y M DY — — — — — — 30 MOR05173 G F T F S N — — H A L S 5 V I S F — — — D G VK F Y A D S V K G 23 Y Y G Y S Y M D Y — — — — — — 30 MOR05174 G F T F SN — — H A L S 5 V I S F — — — D G V K F Y A D S V K G 23 Y Y G Y S Y M DY — — — — — — 30 SEQ ID VH6 G D S V S S N S A A W N 6 R T Y Y R — S K WY N D Y A V S V K S 24 NO MOR04609 G D S V S S N S A A W G 7 R I Y Y R —S K W L N D Y A V S V K S 25 D G G W Y I D V — — — — — — — 31VL Kappa CDR (L-CDR) Sequences Id no. LCDR 1 SEQ ID # LCDR 2 SEQ ID #CDR 3 SEQ ID # SanDI SEQ ID NO Vκ1 R A S Q G I S — — — — — — S Y L A 32A A S S L Q S 41 MOR04493 R A S Q D I Y — — — — — — N Y L N 33 G A S S LQ S 42 Q Q Q N D Y P — — L 50 MOR05008 R A S Q D I Y — — — — — — N Y L N33 G A S S L Q S 42 Q Q Q N D Y P — — L 50 MOR05009 R A S Q D I Y — — —— — — N Y L N 33 G A S S L Q S 42 Q Q Q N D Y P — — L 50 MOR04832 R A SQ D I S — — — — — — I S L T 34 G A F S L Q S 43 Q Q Y Y G T S — — A 51MOR05023 R A S Q D I S — — — — — — I S L T 34 G A F S L Q S 43 Q Q F Y FH S — — P 52 MOR05024 R A S Q D I S — — — — — — I S L T 34 G A F S L Q S43 Q Q F W F E P — — V 53 MOR05025 R A S Q D I S — — — — — — I S L T 34G A F S L Q S 43 Q Q F W F H P — — V 54 MOR05026 R A S Q D I S — — — — —— I S L T 34 G A F S L Q S 43 Q Q F W S E P — — V 55 MOR05027 R A S Q DI S — — — — — — I S L T 34 G A F S L Q S 43 Q Q F W T E P — — V 56SEQ ID NO Vκ3 R A S Q S V S S — — — — — S Y L A 35 G A S S R A T 44MOR04496 R A S Q S I G D — — — — — N Y L A 36 D A N N R A T 45 Q Q Y D DH P — — L 57 VL Lambda CDR (L-CDR) Sequences Id no. CDR 1 SEQ ID # CDR 2SEQ ID # CDR 3 SEQ ID # SEQ ID NO 40 VΛ3 S G D A L G D — — — — — — K Y AS 37 D D S D R P S 46 MOR04494 G G D S L G G — — — — — — K Y V Y 38 G DS K R P S 47 Q S Y T N A L S T — 58 MOR05010 G G D S L G G — — — — — — KY V Y 38 G D S K R P S 47 Q S Y T N A L S T — 58 MOR05011 G G D S L G G— — — — — — K Y V Y 38 G D S K R P S 47 Q S Y T N A L S T — 58 MOR05012G G D S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y T N A L S T— 58 MOR05013 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q SY T N A L S T — 58 MOR05014 G G D S L G G — — — — — — K Y V Y 38 G D S KR P S 47 Q S Y T N A L S T — 58 MOR05015 G G D S L G G — — — — — — K Y VY 38 G D S K R P S 47 Q S Y T N A L S T — 58 MOR05016 G G D S L G G — —— — — — K Y V Y 38 G D S K R P S 47 Q S Y D L Q S L N I 59 MOR05017 G GD S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D L K S L N V 60MOR05018 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D LG S L N L 61 MOR05154 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S47 Q S Y D L Q S L N I 59 MOR05155 G G D S L G G — — — — — — K Y V Y 38G D S K R P S 47 Q S Y D L K S L N V 60 MOR05156 G G D S L G G — — — — —— K Y V Y 38 G D S K R P S 47 Q S Y D L G S L N L 61 MOR05157 G G D S LG G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D L Q S L N I 59MOR05158 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D LK S L N V 60 MOR05159 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S47 Q S Y D L G S L N L 61 MOR05160 G G D S L G G — — — — — — K Y V Y 38G D S K R P S 47 Q S Y D L Q S L N I 59 MOR05161 G G D S L G G — — — — —— K Y V Y 38 G D S K R P S 47 Q S Y D L K S L N V 60 MOR05162 G G D S LG G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D L G S L N L 61MOR05163 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D LQ S L N I 59 MOR05164 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S47 Q S Y D L K S L N V 60 MOR05165 G G D S L G G — — — — — — K Y V Y 38G D S K R P S 47 Q S Y D L G S L N L 61 MOR05166 G G D S L G G — — — — —— K Y V Y 38 G D S K R P S 47 Q S Y D L Q S L N I 59 MOR05167 G G D S LG G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D L K S L N V 60SEQ ID NO 40 VΛ3 S G D A L G D — — — — — — K Y A S 37 D D S D R P S 46MOR04494 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y T NA L S T — 58 MOR05010 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S47 Q S Y T N A L S T — 58 MOR05011 G G D S L G G — — — — — — K Y V Y 38G D S K R P S 47 Q S Y T N A L S T — 58 MOR05012 G G D S L G G — — — — —— K Y V Y 38 G D S K R P S 47 Q S Y T N A L S T — 58 MOR05013 G G D S LG G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y T N A L S T — 58MOR05014 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y T NA L S T — 58 MOR05015 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S47 Q S Y T N A L S T — 58 MOR05016 G G D S L G G — — — — — — K Y V Y 38G D S K R P S 47 Q S Y D L Q S L N I 59 MOR05017 G G D S L G G — — — — —— K Y V Y 38 G D S K R P S 47 Q S Y D L K S L N V 60 MOR05018 G G D S LG G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D L G S L N L 61MOR05154 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D LQ S L N I 59 MOR05155 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S47 Q S Y D L K S L N V 60 MOR05156 G G D S L G G — — — — — — K Y V Y 38G D S K R P S 47 Q S Y D L G S L N L 61 MOR05157 G G D S L G G — — — — —— K Y V Y 38 G D S K R P S 47 Q S Y D L Q S L N I 59 MOR05158 G G D S LG G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D L K S L N V 60MOR05159 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D LG S L N L 61 MOR05160 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S47 Q S Y D L Q S L N I 59 MOR05161 G G D S L G G — — — — — — K Y V Y 38G D S K R P S 47 Q S Y D L K S L N V 60 MOR05162 G G D S L G G — — — — —— K Y V Y 38 G D S K R P S 47 Q S Y D L G S L N L 61 MOR05163 G G D S LG G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D L Q S L N I 59MOR05164 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S 47 Q S Y D LK S L N V 60 MOR05165 G G D S L G G — — — — — — K Y V Y 38 G D S K R P S47 Q S Y D L G S L N L 61 MOR05166 G G D S L G G — — — — — — K Y V Y 38G D S K R P S 47 Q S Y D L Q S L N I 59 MOR05167 G G D S L G G — — — — —— K Y V Y 38 G D S K R P S 47 Q S Y D L K S L N V 60

Annex 2 HuCAL GOLD ® anti-TSLP antibody amino acid sequencesMOR04493 VH, SEQ ID NO: 67:QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPDFGWANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSGMFYSILFDYWGQGTLVTVSS MOR04493 VL, SEQ ID NO: 68:DIQMTQSPSSLSASVGDRVTITCRASQDIYNYLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQQNDY PLTFGQGTKVEIKRTMOR04494 VH, SEQ ID NO: 69:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSNISYDSSDTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARQQYFDHIDIWGQGTLVTVSSMOR04494 VL, SEQ ID NO: 70:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYTNAL STVFGGGTKLTVLGQMOR04496 VH, SEQ ID NO: 71:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAISWVRQAPGKGLEWVSSISYSGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARMEYWYHLLYMDYWGQGTLVTVSS MOR04496 VL, SEQ ID NO: 72:DIVLTQSPATLSLSPGERATLSCRASQSIGDNYLAWYQQKPGQAPRLLIYDANNRATGVPARFSGSGSGTDFTLTISSLEPEDFATYYCQQYDD HPLTFGQGTKVEIKRTMOR04497 VH, SEQ ID NO: 73:QVQLVESGGGLVQPGGSLRLSCAASGFTFSNHALSWVRQAPGKGLEWVSGIQYDGSNTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVY YCARYYGYSYMDYWGQGTLVTVSSMOR04497 VL, SEQ ID NO: 74:DIELTQPPSVSVAPGQTARISCSGDNLGSKYVHWYQQKPGQAPVLVIYADNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDHML QVFGGGTKLTVLGQMOR04609 VH, SEQ ID NO: 75:QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWGWIRQSPGRGLEWLGRIYYRSKWLNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARDGGWYIDVWGQGTLVTVSS MOR04609 VL, SEQ ID NO: 76:DIELTQPPSVSVAPGQTARISCSGDNLGSYYANWYQQKPGQAPVLVIYEDKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSFDSYHS DYVFGGGTKLTVLGQMOR04832 VH, SEQ ID NO: 77:QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGNIYPIFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYGQYGQHFSHGGMDVWGQGTLVTVSS MOR04832 VL, SEQ ID NO: 78:DIQMTQSPSSLSASVGDRVTITCRASQDISISLTWYQQKPGKAPKLLIYGAFSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYGT SATFGQGTKVEIKRTMOR05008 VH, SEQ ID NO: 79:QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPEFGFTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSGMFYSILFDYWGQGTLVTVSS MOR05008 VL, SEQ ID NO: 68:DIQMTQSPSSLSASVGDRVTITCRASQDIYNYLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQQNDY PLTFGQGTKVEIKRTMOR05009 VH, SEQ ID NO: 80:QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGHISPEFGFTNYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARSGMFYSILFDYWGQGTLVTVSS MOR05009 VL, SEQ ID NO: 68:DIQMTQSPSSLSASVGDRVTITCRASQDIYNYLNWYQQKPGKAPKLLIYGASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFAVYYCQQQNDY PLTFGQGTKVEIKRTMOR05010 VH, SEQ ID NO: 81:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGETYYAGSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARQQYFDHIDIWGQGTLVTVSSMOR05010 VL, SEQ ID NO: 70:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYTNAL STVFGGGTKLTVLGQMOR05011 VH, SEQ ID NO: 82:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFYDGSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARQQYFDHIDIWGQGTLVTVSSMOR05011 VL, SEQ ID NO: 70:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYTNAL STVFGGGTKLTVLGQMOR05012 VH, SEQ ID NO: 83:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFTGETYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARQQYFDHIDIWGQGTLVTVSSMOR05012 VL, SEQ ID NO: 70:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYTNAL STVFGGGTKLTVLGQMOR05013 VH, SEQ ID NO: 84:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARQQYFDHIDIWGQGTLVTVSSMOR05013 VL, SEQ ID NO: 70:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYTNAL STVFGGGTKLTVLGQMOR05014 VH, SEQ ID NO: 85:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARQQYFDHIDIWGQGTLVTVSSMOR05014 VL, SEQ ID NO: 70:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYTNAL STVFGGGTKLTVLGQMOR05015 VH, SEQ ID NO: 86:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGTFFDGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARQQYFDHIDIWGQGTLVTVSSMOR05015 VL, SEQ ID NO: 70:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYTNALST VFGGGTKLTVLGQMOR05016 VH, SEQ ID NO: 69:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSNISYDSSDTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARQQYFDHIDIWGQGTLVTVSSMOR05016 VL, SEQ ID NO: 87:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLQSLN IVFGGGTKLTVLGQMOR05017 VH, SEQ ID NO: 69:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSNISYDSSDTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARQQYFDHIDIWGQGTLVTVSSMOR05017 VL, SEQ ID NO: 88:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLKSLN VVFGGGTKLTVLGQMOR05018 VH, SEQ ID NO: 69:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSNISYDSSDTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARQQYFDHIDIWGQGTLVTVSSMOR05018 VL, SEQ ID NO: 89:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLGSLN LVFGGGTKLTVLGQMOR05019 VH, SEQ ID NO: 90:QVQLVESGGGLVQPGGSLRLSCAASGFTFSNHALSWVRQAPGKGLEWVSVISFDGVKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RYYGYSYMDYWGQGTLVTVSSMOR05019 VL, SEQ ID NO: 74:DIELTQPPSVSVAPGQTARISCSGDNLGSKYVHWYQQKPGQAPVLVIYADNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDHMLQV FGGGTKLTVLGQMOR05020 VH, SEQ ID NO: 73:QVQLVESGGGLVQPGGSLRLSCAASGFTFSNHALSWVRQAPGKGLEWVSGIQYDGSNTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARYYGYSYMDYWGQGTLVTVSSMOR05020 VL, SEQ ID NO: 91:DIELTQPPSVSVAPGQTARISCSGDNLGSKYVHWYQQKPGQAPVLVIYADNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYDSNSIR VFGGGTKLTVLGQMOR05021 VH, SEQ ID NO: 73:QVQLVESGGGLVQPGGSLRLSCAASGFTFSNHALSWVRQAPGKGLEWVSGIQYDGSNTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARYYGYSYMDYWGQGTLVTVSSMOR05021 VL, SEQ ID NO: 92:DIELTQPPSVSVAPGQTARISCSGDNLGSKYVHWYQQKPGQAPVLVIYADNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYDLDGVR VFGGGTKLTVLGQMOR05022 VH, SEQ ID NO: 73:QVQLVESGGGLVQPGGSLRLSCAASGFTFSNHALSWVRQAPGKGLEWVSGIQYDGSNTGYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARYYGYSYMDYWGQGTLVTVSSMOR05022 VL, SEQ ID NO: 93:DIELTQPPSVSVAPGQTARISCSGDNLGSKYVHWYQQKPGQAPVLVIYADNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYTTSGIR VFGGGTKLTVLGQMOR05023 VH, SEQ ID NO: 77:QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGNIYPIFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYGQYGQHFSHGGMDVWGQGTLVTVSS MOR05023 VL, SEQ ID NO: 94:DIQMTQSPSSLSASVGDRVTITCRASQDISISLTWYQQKPGKAPKLLIYGAFSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFYFHSP TFGQGTKVEIKRTMOR05024 VH, SEQ ID NO: 77:QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGNIYPIFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYGQYGQHFSHGGMDVWGQGTLVTVSS MOR05024 VL, SEQ ID NO: 95:DIQMTQSPSSLSASVGDRVTITCRASQDISISLTWYQQKPGKAPKLLIYGAFSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFWFEPV TFGQGTKVEIKRTMOR05025 VH, SEQ ID NO: 77:QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGNIYPIFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYGQYGQHFSHGGMDVWGQGTLVTVSS MOR05025 VL, SEQ ID NO: 96:DIQMTQSPSSLSASVGDRVTITCRASQDISISLTWYQQKPGKAPKLLIYGAFSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFWFHPV TFGQGTKVEIKRTMOR05026 VH, SEQ ID NO: 77:QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGNIYPIFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYGQYGQHFSHGGMDVWGQGTLVTVSS MOR05026 VL, SEQ ID NO: 97:DIQMTQSPSSLSASVGDRVTITCRASQDISISLTWYQQKPGKAPKLLIYGAFSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFWSEPV TFGQGTKVEIKRTMOR05027 VH, SEQ ID NO: 77:QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGNIYPIFGYANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYGQYGQHFSHGGMDVWGQGTLVTVSS MOR05027 VL, SEQ ID NO: 98:DIQMTQSPSSLSASVGDRVTITCRASQDISISLTWYQQKPGKAPKLLIYGAFSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFWTEPV TFGQGTKVEIKRTMOR05154 VH, SEQ ID NO: 81:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGETYYAGSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05154 VL, SEQ ID NO: 87:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLQSLN IVFGGGTKLTVLGQMOR05155 VH, SEQ ID NO: 81:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGETYYAGSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05155 VL, SEQ ID NO: 88:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLKSLN VVFGGGTKLTVLGQMOR05156 VH, SEQ ID NO: 81:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGETYYAGSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05156 VL, SEQ ID NO: 89:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLGSLN LVFGGGTKLTVLGQMOR05157 VH, SEQ ID NO: 82:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFYDGSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05157 VL, SEQ ID NO: 87:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLQSLN IVFGGGTKLTVLGQMOR05158 VH, SEQ ID NO: 82:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFYDGSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05158 VL, SEQ ID NO: 88:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLKSLN VVFGGGTKLTVLGQMOR05159 VH, SEQ ID NO: 82:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFYDGSTYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05159 VL, SEQ ID NO: 89:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLGSLN LVFGGGTKLTVLGQMOR05160 VH, SEQ ID NO: 83:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFTGETYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05160 VL, SEQ ID NO: 87:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLQSLN IVFGGGTKLTVLGQMOR05161 VH, SEQ ID NO: 83:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFTGETYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05161 VL, SEQ ID NO: 88:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLKSLN VVFGGGTKLTVLGQMOR05162 VH, SEQ ID NO: 83:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFTGETYYPDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05162 VL, SEQ ID NO: 89:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLGSLN LVFGGGTKLTVLGQMOR05163 VH, SEQ ID NO: 84:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05163 VL, SEQ ID NO: 87:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLQSLN IVFGGGTKLTVLGQMOR05164 VH, SEQ ID NO: 84:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05164 VL, SEQ ID NO: 88:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLKSLN VVFGGGTKLTVLGQMOR05165 VH, SEQ ID NO: 84:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05165 VL, SEQ ID NO: 89:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLGSLN LVFGGGTKLTVLGQMOR05166 VH, SEQ ID NO: 85:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05166 VL, SEQ ID NO: 87:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLQSLN IVFGGGTKLTVLGQMOR05167 VH, SEQ ID NO: 85:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05167 VL, SEQ ID NO: 88:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLKSLN VVFGGGTKLTVLGQMOR05168 VH, SEQ ID NO: 85:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05168 VL, SEQ ID NO: 89:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLGSLN LVFGGGTKLTVLGQMOR05169 VH, SEQ ID NO: 86:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGTFFDGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05169 VL, SEQ ID NO: 87:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLQSLN IVFGGGTKLTVLGQMOR05170 VH, SEQ ID NO: 86:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGTFFDGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05170 VL, SEQ ID NO: 88:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLKSLN VVFGGGTKLTVLGQMOR05171 VH, SEQ ID NO: 86:QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGTFFDGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RQQYFDHIDIWGQGTLVTVSSMOR05171 VL, SEQ ID NO: 89:DIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLGSLN LVFGGGTKLTVLGQMOR05172 VH, SEQ ID NO: 90:QVQLVESGGGLVQPGGSLRLSCAASGFTFSNHALSWVRQAPGKGLEWVSVISFDGVKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RYYGYSYMDYWGQGTLVTVSSMOR05172 VL, SEQ ID NO: 91:DIELTQPPSVSVAPGQTARISCSGDNLGSKYVHWYQQKPGQAPVLVIYADNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYDSNSIR VFGGGTKLTVLGQMOR05173 VH, SEQ ID NO: 90:QVQLVESGGGLVQPGGSLRLSCAASGFTFSNHALSWVRQAPGKGLEWVSVISFDGVKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RYYGYSYMDYWGQGTLVTVSSMOR05173 VL, SEQ ID NO: 92:DIELTQPPSVSVAPGQTARISCSGDNLGSKYVHWYQQKPGQAPVLVIYADNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYDLDGVR VFGGGTKLTVLGQMOR05174 VH, SEQ ID NO: 90:QVQLVESGGGLVQPGGSLRLSCAASGFTFSNHALSWVRQAPGKGLEWVSVISFDGVKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA RYYGYSYMDYWGQGTLVTVSSMOR05174 VL, SEQ ID NO: 93:DIELTQPPSVSVAPGQTARISCSGDNLGSKYVHWYQQKPGQAPVLVIYADNNRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSSYTTSGIR VFGGGTKLTVLGQMOR 5164, 5167, 5170 LIGHTCHAIN LAMBDAThe LC Lamda amino acid sequence is shown inSEQ ID NO: 99: and is encoded by the nucleotidesequence of SEQ ID NO: 100: (SEQ ID NO: 99:)MAWALLLLTLLTQGTGSWADIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLKSLNVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 100:)ATGGCCTGGGCTCTGCTGCTCCTCACCCTCCTCACTCAGGGCACAGGATCCTGGGCTGATATCGAACTGACCCAGCCGCCTTCAGTGAGCGTTGCACCAGGTCAGACCGCGCGTATCTCGTGTGGCGGCGATTCTCTTGGTGGTAAGTATGTTTATTGGTACCAGCAGAAACCCGGGCAGGCGCCAGTTCTTGTGATTTATGGTGATTCTAAGCGTCCCTCAGGCATCCCGGAACGCTTTAGCGGATCCAACAGCGGCAACACCGCGACCCTGACCATTAGCGGCACTCAGGCGGAAGACGAAGCGGATTATTATTGCCAGTCTTATGATCTTAAGTCTCTTAATGTTGTGTTTGGCGGCGGCACGAAGTTAACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTACAGAATGTTCAMOR 5164, 5167, 5170 LIGHT CHAIN LAMBDA (OPTIMIZED)The LC Lamda amino acid sequence is shown inSEQ ID NO: 101: and is encoded by thenucleotide sequence of SEQ ID NO: 102: (SEQ ID NO: 101:)MSVLTQVLALLLLWLTGTRCDIELTQPPSVSVAPGQTARISCGGDSLGGKYVYWYQQKPGQAPVLVIYGDSKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCQSYDLKSLNVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 102)ATGAGTGTGCTCACTCAGGTCCTGGCGTTGCTGCTGCTGTGGCTTACAGGTACGCGTTGCGACATCGAGCTGACCCAGCCCCCCAGCGTGTCTGTGGCCCCTGGCCAGACCGCCCGGATCAGCTGTGGCGGCGACAGCCTGGGCGGCAAGTACGTGTACTGGTATCAGCAGAAGCCCGGCCAGGCCCCCGTGCTGGTGATCTACGGCGACAGCAAGCGGCCCAGCGGCATCCCCGAGCGGTTCAGCGGCAGCAACAGCGGCAACACCGCCACCCTGACCATCAGCGGCACCCAGGCCGAGGACGAGGCCGACTACTACTGCCAGAGCTACGACCTGAAGAGCCTGAACGTGGTGTTTGGCGGCGGAACAAAGCTTACCGTCCTAGGTCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCCTCTGAGGAGCTTCAAGCCAACAAGGCCACACTGGTGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGGAGTGGAGACAACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTATCTGAGCCTGACGCCTGAGCAGTGGAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAAAAGACAGTGGCCCCTACAGAATGTTCATA GMOR5164 HEAVY CHAIN IgG1: The HC Lamda amino acid sequence is shown inSEQ ID NO: 103 and is encoded by thenucleotide sequence of SEQ ID NO: 104 (SEQ ID NO: 103)MKHLWFFLLLVAAPRWVLSQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQQYFDHIDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 104)ATGAAACACCTGTGGTTCTTCCTCCTGCTGGTGGCAGCTCCCAGATGGGTCCTGTCCCAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTATATGTCTTGGGTGCGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATTTTTTTTGATGGTGAGACTTATTATGCTGATTCTGTTAAGGGTCGTTTTACCATTTCACGTGATAATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTCAGCAGTATTTTGATCATATTGATATTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAMOR5164 HEAVY CHAIN IgG1 (OPTIMIZED)The HC Lamda amino acid sequence is shown inSEQ ID NO: 105 and is encoded by thenucleotide sequence of SEQ ID NO: 106 (SEQ ID NO: 105)MAWVWTLPFLMAAAQSVQAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGETYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQQYFDHIDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 106)ATGGCTTGGGTGTGGACCTTGCCATTCCTGATGGCAGCTGCCCAAAGTGTCCAGGCCCAGGTGCAGCTGGTGGAATCTGGCGGCGGACTGGTGCAGCCTGGCGGCAGCCTGAGACTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACTACATGAGCTGGGTGCGGCAGGCCCCTGGCAAGGGCCTGGAATGGGTGTCCGGCATCTTCTTCGACGGCGAGACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCAGCAGTACTTCGACCACATCGACATCTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTCGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA MOR5167 HEAVY CHAIN IgG1:The HC Lamda amino acid sequence is shown inSEQ ID NO: 107 and is encoded by thenucleotide sequence of SEQ ID NO: 108 (SEQ ID NO: 107)MKHLWFFLLLVAAPRWVLSQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQQYFDHIDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 108)ATGAAACACCTGTGGTTCTTCCTCCTGCTGGTGGCAGCTCCCAGATGGGTCCTGTCCCAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTATATGTCTTGGGTGCGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATTTTTTTTGATGGTACTACTTATTATGCTGATTCTGTTAAGGGTCGTTTTACCATTTCACGTGATAATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTCAGCAGTATTTTGATCATATTGATATTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAMOR5167 HEAVY CHAIN IgG1 (OPTIMIZED):The HC Lamda amino acid sequence is shown inSEQ ID NO: 109 and is encoded by thenucleotide sequence of SEQ ID NO: 110 (SEQ ID NO: 109)MAWVWTLPFLMAAAQSVQAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGIFFDGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQQYFDHIDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 110)ATGGCTTGGGTGTGGACCTTGCCATTCCTGATGGCAGCTGCCCAAAGTGTCCAGGCCCAGGTGCAGCTGGTGGAATCTGGCGGCGGACTGGTGCAGCCTGGCGGCAGCCTGAGACTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACTACATGAGCTGGGTGCGGCAGGCCCCTGGCAAGGGCCTGGAATGGGTGTCCGGCATCTTCTTCGACGGCACCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCAGCAGTACTTCGACCACATCGACATCTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTCGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA MOR5170 HEAVY CHAIN IgG1:The HC Lamda amino acid sequence is shown inSEQ ID NO: 111 and is encoded by thenucleotide sequence of SEQ ID NO: 112 (SEQ ID NO: 111)MKHLWFFLLLVAAPRWVLSQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGTFFDGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQQYFDHIDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHNQDWLGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 112)ATGAAACACCTGTGGTTCTTCCTCCTGCTGGTGGCAGCTCCCAGATGGGTCCTGTCCCAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTTCTTCTTATTATATGTCTTGGGTGCGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGGTACTTTTTTTGATGGTTCTACTTATTATGCTGATTCTGTTAAGGGTCGTTTTACCATTTCACGTGATAATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACGGCCGTGTATTATTGCGCGCGTCAGCAGTATTTTGATCATATTGATATTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCAGCCTCCACCAAGGGTCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAMOR5170 HEAVY CHAIN IgG1 (OPTIMIZED):The HC Lamda amino acid sequence is shown inSEQ ID NO: 113 and is encoded by thenucleotide sequence of SEQ ID NO: 114 (SEQ ID NO: 113)MAWVWTLPFLMAAAQSVQAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYYMSWVRQAPGKGLEWVSGTFFDGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQQYFDHIDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 114)ATGGCTTGGGTGTGGACCTTGCCATTCCTGATGGCAGCTGCCCAAAGTGTCCAGGCCCAGGTGCAGCTGGTGGAATCTGGCGGCGGACTGGTGCAGCCTGGCGGCAGCCTGAGACTGAGCTGCGCCGCCAGCGGCTTCACCTTCAGCAGCTACTACATGAGCTGGGTGCGGCAGGCCCCTGGCAAGGGCCTGGAATGGGTGTCCGGCACCTTCTTCGACGGCAGCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACAACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGGCAGCAGTACTTCGACCACATCGACATCTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTCGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTATAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCCCCGGGTAAATGA

1. An isolated human or humanized antibody or functional fragmentthereof comprising an antigen-binding region that is specific for humanTSLP, wherein the antibody or functional fragment thereof binds humanTSLP with a KD of 39×10⁻¹² M or less.
 2. The antibody or functionalfragment thereof according to claim 1, wherein the antibody orfunctional fragment thereof binds human TSLP with a KD of 14×10⁻¹² M orless.
 3. The antibody or functional fragment thereof according to claim1 which comprises an H-CDR1 region depicted in the amino acid sequenceof SEQ ID NO: 3, an H-CDR2 region depicted in an amino acid sequenceselected from the group of SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18,SEQ ID NO: 19 and SEQ ID NO: 20, an H-CDR3 region depicted in the aminoacid sequence SEQ ID NO: 28, an L-CDR1 region depicted in the amino acidsequence of SEQ ID NO: 38, an L-CDR2 region depicted in the amino acidsequence SEQ ID NO: 47, and an L-CDR3 region depicted in the amino acidsequence SEQ ID NO: 60, and conservative variants thereof.
 4. Theantibody or functional fragment thereof according to claim 3 whichcomprises an H-CDR1 region depicted in the amino acid sequence of SEQ IDNO: 3, an H-CDR2 region depicted in an amino acid sequence selected fromthe group of SEQ ID NO: 20, and an H-CDR3 region depicted in the aminoacid sequence SEQ ID NO: 28, an L-CDR1 region depicted in the amino acidsequence of SEQ ID NO: 38, an L-CDR2 region depicted in the amino acidsequence SEQ ID NO: 47, and an L-CDR3 region depicted in the amino acidsequence SEQ ID NO: 60 and conservative variants thereof.
 5. Theantibody or functional fragment thereof according to claim 3 whichcomprises a sequence having at least 60, 70, 80, 90 or 95 percentsequence identity in the CDR regions.
 6. The isolated antibody accordingto claim 1, which is an IgG1, IgG2 or an IgG4.
 7. The isolated antibodyaccording to claim 6 comprising a heavy chain variable region selectedfrom SEQ ID NO: 84, SEQ ID NO: 85 and SEQ ID NO: 86, and conservativevariants thereof.
 8. The isolated antibody according to claim 7comprising the light chain variable region SEQ ID NO:
 88. 9. Theisolated antibody according to claim 7 where the heavy chain variableregion is SEQ ID NO: 84, and conservative variants thereof.
 10. Theisolated antibody according to claim 7 where the heavy chain variableregion is SEQ ID NO: 85, and conservative variants thereof.
 11. Theisolated antibody according to claim 7 where the heavy chain variableregion is SEQ ID NO: 86, and conservative variants thereof.
 12. Theisolated antibody according to claim 7 which is an IgG1 having a lightchain lamda sequence selected from SEQ ID NO: 99 or SEQ ID NO: 101, anda heavy chain sequence selected from SEQ ID NO: 103, SEQ ID No: 105, SEQID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111 and SEQ ID NO: 113, andconservative variants thereof.
 13. An isolated or recombinantpolynucleotide which encodes a polypeptide comprising an antigen-bindingregion of an antibody or functional fragment thereof according toclaim
 1. 14. The polynucleotide of claim 13, wherein the antibody is ahuman antibody.
 15. The polynucleotide of claim 13, wherein thepolynucleotide encodes am antibody comprising H-CDR1, H-CDR2, and H-CDR3sequences, and L-CDR1, L-CDR2, and L-CDR3 sequences, selected from: (a)H-CDR SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 28; L-CDR SEQ ID NO: 38,SEQ ID NO: 47, SEQ ID NO:
 60. (b) H-CDR SEQ ID NO: 3, SEQ ID NO: 17, SEQID NO: 28; L-CDR SEQ ID NO: 38, SEQ ID NO: 47, SEQ ID NO:
 60. (c) H-CDRSEQ ID NO: 3, SEQ ID NO: 18, SEQ ID NO: 28; L-CDR SEQ ID NO: 38, SEQ IDNO: 47, SEQ ID NO:
 60. (d) H-CDR SEQ ID NO: 3, SEQ ID NO: 19, SEQ ID NO:28; L-CDR SEQ ID NO: 38, SEQ ID NO: 47, SEQ ID NO:
 60. (e) H-CDRSEQ IDNO: 3, SEQ ID NO: 20, SEQ ID NO: 28; and L-CDR SEQ ID NO: 38, SEQ ID NO:47, SEQ ID NO:
 60. 16. The polynucleotide of claim 13 which is a DNA.17. An isolated host cell comprising (1) a recombinant DNA segmentencoding a heavy chain of the antibody of claim 7, and (2) a secondrecombinant DNA segment encoding a light chain of the antibody; whereinsaid DNA segments are respectively operably linked to a first and asecond promoter, and are capable of being expressed in said host cell.18. The host cell of claim 17, wherein the monoclonal antibody is ahuman antibody.
 19. The host cell of claim 17, wherein the monoclonalantibody comprises a heavy and light chain sequence selected from: (a)H-CDR SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 28; L-CDR SEQ ID NO: 38,SEQ ID NO: 47, SEQ ID NO:
 60. (b) H-CDR SEQ ID NO: 3, SEQ ID NO: 17, SEQID NO: 28; L-CDR SEQ ID NO: 38, SEQ ID NO: 47, SEQ ID NO:
 60. (c) H-CDRSEQ ID NO: 3, SEQ ID NO: 18, SEQ ID NO: 28; L-CDR SEQ ID NO: 38, SEQ IDNO: 47, SEQ ID NO:
 60. (d) H-CDR SEQ ID NO: 3, SEQ ID NO: 19, SEQ ID NO:28; L-CDR SEQ ID NO: 38, SEQ ID NO: 47, SEQ ID NO:
 60. (e) H-CDRSEQ IDNO: 3, SEQ ID NO: 20, SEQ ID NO: 28; and L-CDR SEQ ID NO: 38, SEQ ID NO:47, SEQ ID NO:
 60. 20. The host cell of claim 17 that is a non-humanmammalian cell line.
 21. A pharmaceutical composition comprising anantibody or functional fragment thereof according to claim 1 and apharmaceutically acceptable carrier or excipient therefor.
 22. Thepharmaceutical composition according to claim 21 for use in treating adisorder or condition associated with the presence of cell receptortarget hTSLP, wherein the composition is administered to a subject inneed thereof in an effective amount.
 23. The pharmaceutical compositionaccording to claim 22, wherein the disorder or condition is asthma. 24.The pharmaceutical composition according to claim 22, wherein thedisorder or condition is atopic dermatitis.